US.MRNA · Moderna

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 11.676338361763221,
        "turnoverUsdM": 3390.7340959671697,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.3
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRNA",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 152.4132,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 23.4,
      "take_profit_price": 234.142,
      "target_multiplier": 1.6,
      "technical_strength": 1.43,
      "take_profit_percent": 17.7
    },
    "positionPoints": 1.1,
    "stopLossPoints": 0.6,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 15,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 44.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 43.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 1
  },
  "market": {
    "ma20": 210.5645,
    "ma50": 173.8566,
    "close": 198.85,
    "prevClose": 200.1,
    "avgVolume20": 20026786,
    "volumeRatio": 0.85,
    "changePercent": -0.62
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 1,
    "details": {
      "ret_5d": -0.12358407157653484,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 1,
      "vcp_bonus": 0,
      "vol_ratio": 0.8593671159116589,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.1420520139581358,
      "volat_points": 0,
      "day_range_pct": 0.11144082919583459,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 44.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 4.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 29.33,
        "contribution": 4.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.1,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 51,
        "contribution": 5.1
      },
      {
        "raw": 15.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 52.33,
        "contribution": 15.7
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 43.7,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 4.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.1/10分",
      "技術信號分析總分: 15.7/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.5,
      "資金流": 10,
      "市場環境": 4.4,
      "情緒分析": 4,
      "技術信號": 15.7,
      "風險管理": 5.1
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0.75,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 3390.7340959671697,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 2.4,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRNA",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 19.45
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 734.0185023500001,
                "ma50": 725.4347994000001,
                "name": "QQQ",
                "close": 712.20001,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.1384979000001,
                "ma50": 767.5889950999999,
                "name": "SPY",
                "close": 765.37,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 11.676338361763221,
          "atrPoints": 1,
          "cciPoints": 0.8,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143180859,
                "url": "https://finnhub.io/api/news?id=2b8144f6c9043eb783c3fd3d71a8ea7cda9e816222edc18d994c372b16ed6c88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has delivered a very large gain over the past year, even after a sharp recent pullback. This puts fresh attention on whether its current share price is supported by the sales investors are effectively paying for. With headlines around vaccine trial data and new product approvals, the question is how much revenue the current valuation already assumes. The stock has risen by roughly 7x over the past 12 months. This raises the question of how much future top line progress the current...",
                "category": "company",
                "datetime": 1792933669,
                "headline": "Moderna (MRNA) Stock May Be Fully Priced As Melanoma Vaccine Data Leaks"
              },
              {
                "id": 143168462,
                "url": "https://finnhub.io/api/news?id=a16123f6187bf8b266a35175b7eac40fe4c6c948e96bce13451afe9854712b62",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy October 24, 2026 1:00 PM EDTCompany ParticipantsDavid...",
                "category": "company",
                "datetime": 1792868234,
                "headline": "Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript"
              },
              {
                "id": 143136269,
                "url": "https://finnhub.io/api/news?id=078d4492b68de2d6e69cef66f0facd333e0d494ca796921d79b640fe4efc1e40",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna falls despite positive phase III cancer therapy data showing reduced melanoma recurrence and metastasis risks, as investors weigh elevated expectations.",
                "category": "company",
                "datetime": 1792768080,
                "headline": "MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress"
              },
              {
                "id": 143133474,
                "url": "https://finnhub.io/api/news?id=ed12e584f4cf1f3c6ddfea388acf97feb4398507d99cef7b2347e92c993a41ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "According to The Fly, multiple analysts commented on Moderna’s Phase 3 melanoma-vaccine data, with Bernstein describing the stock’s decline as a “sell the news event” and TD Cowen calling the leaked results “compelling” .",
                "category": "company",
                "datetime": 1792760656,
                "headline": "MRNA Stock: Citi Questions Whether Melanoma Vaccine’s Benefit Justifies Individualized Tumor Harvesting And Manufacturing"
              },
              {
                "id": 143128984,
                "url": "https://finnhub.io/api/news?id=5922972d586f65fcf83214c46c06e90ef1c3a8fbb7f6857fb86f2fb48028df32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stocktwits retail sentiment for SPY and DIA was ‘extremely bearish,’ while it remained ‘bearish’ for QQQ.",
                "category": "company",
                "datetime": 1792750428,
                "headline": "Nasdaq, Dow, S&P 500 Futures Drop Premarket: NVDA, AMD, META, CRWV, MRNA, WDC, BE In Focus"
              },
              {
                "id": 143112300,
                "url": "https://finnhub.io/api/news?id=14ce11132406f5225a528e25eed0faa1eb1f096d9f796ad378b19c0c849254fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its personalized cancer vaccine leaked ahead of a planned presentation this weekend, and the stock sold off hard even though the results themselves look positive. According to CNBC, shares fell as much as 25% after an early look at the vaccine Moderna is developing with Merck, intismeran autogene, showed up online before it was supposed to be presented at the Eur",
                "category": "company",
                "datetime": 1792721153,
                "headline": "Why Moderna (MRNA) stock is trading lower today"
              },
              {
                "id": 143110890,
                "url": "https://finnhub.io/api/news?id=a93087b565be4402a09f764630c5f9ce6c76c82457785cdd8843f4bc756767ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.",
                "category": "company",
                "datetime": 1792718929,
                "headline": "MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings"
              },
              {
                "id": 143105051,
                "url": "https://finnhub.io/api/news?id=a63d881206482be9a6bc6fbf2bb9f71020d5154a1e81795bbd077716db89c988",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Meta’s plan to boost capex reignited investor concerns as more tech firms look to raise debt to fund AI growth.",
                "category": "company",
                "datetime": 1792712688,
                "headline": "Nasdaq 100 Clocks Worst Day In Four Months As Investors Grow Weary Of Capex, Elevated Debt — META, SPCX, BE, MRNA In Focus"
              }
            ],
            "raw_source": [
              {
                "id": 143202666,
                "url": "https://finnhub.io/api/news?id=13e38c2b404ba1ca3667681b7b628042dc8870c55963b9f3a1fa8fac88b361dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Key TakeawaysModerna shares fell another 8% this morning. On Saturday it and its partner Merck presented full Phase 3 data showing their personalized melanoma vaccine cut the risk of recurrence or death by 42%.",
                "category": "company",
                "datetime": 1793042897,
                "headline": "Moderna Sinks Another 8% Even as Lead Investigator Calls Melanoma Vaccine Data “Transformational”"
              },
              {
                "id": 143203587,
                "url": "https://finnhub.io/api/news?id=37151b5ed45ab3eef649ed00858fc1a8ecd43db7c9c735bf38c9542015468224",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however, be too late to play the forces behind its rise.",
                "category": "company",
                "datetime": 1793042237,
                "headline": "Moderna’s Rally May Have Run Out of Steam. Here’s What to Watch Next"
              },
              {
                "id": 143201698,
                "url": "https://finnhub.io/api/news?id=cac2f82db5fe8c93f5074d423cf220a4f5cda77704b0b5f8b716c0e2c5b804a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.",
                "category": "company",
                "datetime": 1793030280,
                "headline": "ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data"
              },
              {
                "id": 143203614,
                "url": "https://finnhub.io/api/news?id=dc4dded256db86d44037f30b465cba8b0e2ba368211ca6fb1bbfab8c24920f27",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 gap-down stocks from the Oct. 26, 2026 session, including FICO, MRNA, RDDT, EQT, OMC, CNC, PYPL, BRO, NFLX and EFX, with gap, move and latest price.",
                "category": "company",
                "datetime": 1793028970,
                "headline": "S&P 500 Gap-Down Stocks for Oct. 26, 2026"
              },
              {
                "id": 143200300,
                "url": "https://finnhub.io/api/news?id=73214f01c4b7ef315b6d4ddac2c7adef494f577327e964126ac52baec1855af1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Amgen showcases “excellent” data for its small-cell lung cancer treatment following leaked results for Moderna and Merck’s intismeran autogene.",
                "category": "company",
                "datetime": 1793026320,
                "headline": "Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show."
              },
              {
                "id": 143200301,
                "url": "https://finnhub.io/api/news?id=824c3262d9c4f623ec151bd6bfd8b0dda64a06d553cf71f329a1c9d6e5532d28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT.",
                "category": "company",
                "datetime": 1793024828,
                "headline": "Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine"
              },
              {
                "id": 143197201,
                "url": "https://finnhub.io/api/news?id=25ba0a16c32b25a6eb4091c6ac82b41a620415d56cc52a92aa6a7b0097715d3c",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 premarket movers include COHR, ROST, LITE, TSLA, FICO, MRNA, EQT and others, with premarket gains and declines ahead of the opening bell.",
                "category": "company",
                "datetime": 1793021768,
                "headline": "S&P 500 Premarket Movers: Gainers and Losers Before the Open"
              },
              {
                "id": 143197127,
                "url": "https://finnhub.io/api/news?id=42f99c9c4d4b3abbf468367861f854b0aab6b2e05fb3a861f13e83823d0455fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's personalized melanoma vaccine cleared its primary hurdle in a late-stage trial, yet shares are sinking fast. The gap between what the data promised and what it delivered is forcing traders to rethink how much the company's flagship cancer bet is actually worth.",
                "category": "company",
                "datetime": 1793020442,
                "headline": "Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady"
              },
              {
                "id": 143197338,
                "url": "https://finnhub.io/api/news?id=7fac3686738df5b8114999b4b64962805e303e362758785aeda2fcaa79e64eff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Lilly and Merck boast blockbuster drugs, expanding pipelines and new growth opportunities but pricing pressure, patent risks & competition shape their outlooks.",
                "category": "company",
                "datetime": 1793017800,
                "headline": "LLY vs. MRK: Which Stock Offers the More Compelling Investment Case?"
              },
              {
                "id": 143195363,
                "url": "https://finnhub.io/api/news?id=3108bb9944de46ac15869e0b6d5e084355e552cf6805860a390718c435434128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investing.com - U.S. stock index futures rose on Monday after technology-driven losses battered Wall Street in the previous session, with investors turning their attention to this week’s Federal Reserve policy announcement and a slate of major corporate earnings.",
                "category": "company",
                "datetime": 1793015788,
                "headline": "Premarket movers: Moderna, Brazil ADRs drop; SpaceX rises"
              },
              {
                "id": 143200520,
                "url": "https://finnhub.io/api/news?id=0e28af710d5a368ed5b56be7c6c9cf0302984ed33b393f3291edc6f079ec7cb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna will release its third-quarter earnings next week, and analysts anticipate a triple-digit loss dip.",
                "category": "company",
                "datetime": 1793006879,
                "headline": "Here's What to Expect From Moderna's Next Earnings Report"
              },
              {
                "id": 143197505,
                "url": "https://finnhub.io/api/news?id=4aa5b639ff35284e330f5cf78fe56000340f0fcce81c7d7959a208ac64332bb6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/26/Kyiv--Ukraine---December-01--2020-Modern.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna’s stock went on a wild ride last week that included a data leak and a dramatic tale from a social media influencer.",
                "category": "company",
                "datetime": 1793005583,
                "headline": "Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing"
              },
              {
                "id": 143197515,
                "url": "https://finnhub.io/api/news?id=8f594fedf81d97f8df521cb668d3d5a3025a846bbe76ae37cef50ed1027dd8ce",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/26/Section-Of-A-Financial-Newspaper-Titled-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Brazilian stocks plunged premarket after Lula's reelection, led by XP (-46%), Inter & Co (-34.7%), StoneCo (-33.8%) and MercadoLibre (-14.1%).",
                "category": "company",
                "datetime": 1793001730,
                "headline": "MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session"
              },
              {
                "id": 143182205,
                "url": "https://finnhub.io/api/news?id=5163ce18942b895f4e4b097d7595eb2c4b40eccba1b2953b30ce4795c2fbca01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Twenty-two companies have now objected to having their shares traded on the planned OKX-ICE tokenized stock venue, after Wells Fargo, Cisco, Marvell, Arm, Moderna. and Intuit joined the list.",
                "category": "company",
                "datetime": 1792944063,
                "headline": "Wells Fargo, Cisco, Intuit Among 6 More Companies Objecting to Tokenized Stocks"
              },
              {
                "id": 143181450,
                "url": "https://finnhub.io/api/news?id=68b927313b4c11ff536ac4cb4fc3a7db02602efb134fc4c34962698ed843f72b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Merck (NYSE:MRK) reports third-quarter results on Thursday, Oct. 29. KEYTRUDA still anchors the business, but I’ll be watching whether newer launches are growing fast enough to cushion the drug’s 2028 patent loss. New Launches Are Carrying More of the Load Last quarter, revenue rose 5.07% to $16.61 billion, beating the $16.37 billion consensus. The non-GAAP […]",
                "category": "company",
                "datetime": 1792942272,
                "headline": "Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck’s Q3 Results on Oct. 29"
              },
              {
                "id": 143180859,
                "url": "https://finnhub.io/api/news?id=2b8144f6c9043eb783c3fd3d71a8ea7cda9e816222edc18d994c372b16ed6c88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has delivered a very large gain over the past year, even after a sharp recent pullback. This puts fresh attention on whether its current share price is supported by the sales investors are effectively paying for. With headlines around vaccine trial data and new product approvals, the question is how much revenue the current valuation already assumes. The stock has risen by roughly 7x over the past 12 months. This raises the question of how much future top line progress the current...",
                "category": "company",
                "datetime": 1792933669,
                "headline": "Moderna (MRNA) Stock May Be Fully Priced As Melanoma Vaccine Data Leaks"
              },
              {
                "id": 143168815,
                "url": "https://finnhub.io/api/news?id=36496c13e3aa0140f6b806a54569f570dadc198bbce8eab0d2dcabd99315d3c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di",
                "category": "company",
                "datetime": 1792879323,
                "headline": "Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial"
              },
              {
                "id": 143168462,
                "url": "https://finnhub.io/api/news?id=a16123f6187bf8b266a35175b7eac40fe4c6c948e96bce13451afe9854712b62",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy October 24, 2026 1:00 PM EDTCompany ParticipantsDavid...",
                "category": "company",
                "datetime": 1792868234,
                "headline": "Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript"
              },
              {
                "id": 143166289,
                "url": "https://finnhub.io/api/news?id=2391ec4b0e4c9481dcfb26288532abf7825f3cfebdbf86ec4b110d9fbe3a23f6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1216889071/image_1216889071.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna, Inc.’s melanoma trial with Keytruda cut recurrence risk 42%, but rich valuation tempers upside. Click for this MRNA update.",
                "category": "company",
                "datetime": 1792852282,
                "headline": "Moderna: Why Positive Phase 3 Results Weren't Enough"
              },
              {
                "id": 143182047,
                "url": "https://finnhub.io/api/news?id=4282034fb46ed1a168f38222c0ad196b6b6c83abe76b44c786919ce4aed3ac84",
                "image": "https://image.cnbcfm.com/api/v1/image/108100625-1739282958280-gettyimages-2151784607-MODERNA_RSV_VACCINE.jpeg?v=1792438619&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.",
                "category": "company",
                "datetime": 1792833045,
                "headline": "Biotech stocks are surging. How investors can play the new drug innovation boom"
              },
              {
                "id": 143136966,
                "url": "https://finnhub.io/api/news?id=c7dc74858f1bf1f0285200109a09d022ccc5fbaea3e64a0150f6db56ef2f5294",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients and investors all learning whether a novel medicine will make a meaningful difference in people's lives and forming the same conclusion. Instead, as reports leaked out on social media about the findings of the melanoma shot   days before the carefully scripted presentation planned for thousands of oncologists gathered in Madrid for the European Society for Medical Oncology meeting   realities diverged.  Madison Muller, Bloomberg News Healthcare Reporter, reports.",
                "category": "company",
                "datetime": 1792785866,
                "headline": "Oncologists Cheer Melanoma Data"
              },
              {
                "id": 143136688,
                "url": "https://finnhub.io/api/news?id=03f151951b7c0f2f9e114d2cfe06c89f37fb6a64f57c5a572b616d670ec67d7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investing.com -- Cybersecurity names gained ground on a global software alert while Meta declined and a fresh escalation in the Middle East pushed crude to highs.",
                "category": "company",
                "datetime": 1792780173,
                "headline": "Investing.com’s stocks of the week"
              },
              {
                "id": 143136881,
                "url": "https://finnhub.io/api/news?id=677b3233e6394270f95189eda22ec56482302cc39db82cf77662bc002543adf2",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Most-active S&P 500 scan for Oct. 23, 2026 ranks AT&T, Verizon, Bloom Energy, Ford, Netflix and others by volume with price moves and performance context.",
                "category": "company",
                "datetime": 1792778757,
                "headline": "Most Active S&P 500 Stocks for Oct. 23, 2026"
              },
              {
                "id": 143136268,
                "url": "https://finnhub.io/api/news?id=f852edab07ff8dae6cc3c7b5e4e7925c3def0b561cc21b3530907f42d85ccc0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.",
                "category": "company",
                "datetime": 1792771891,
                "headline": "Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?"
              },
              {
                "id": 143135654,
                "url": "https://finnhub.io/api/news?id=e0e62b87f516f3a6d06bbfbe53983a1ef34f576818d05ad0b14c7468fd628d0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In an interview with CNBC, Merck CEO Rob Davis said the company is confident it can deliver Intismeran at scale.",
                "category": "company",
                "datetime": 1792769639,
                "headline": "Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’"
              },
              {
                "id": 143135746,
                "url": "https://finnhub.io/api/news?id=ca830e29dd7714c8ccc98a91b5f6e6aadcadbff53c337b8458b8d53cbf908056",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "On this episode of Stock Movers: - Decker Outdoor (DECK) is tumbling after the footwear company cut its net sales guidance for the full year, which also fell short of the consensus estimate. - Kering (KER) shares are slumping after the French luxury-goods company saw further deceleration of third-quarter revenue growth at its key Gucci unit, slower growth in North America as well as persistent weakness in China. - American Express (AXP) shares are moving on news that the company is planning to cut 5% of its global headcount. Chief Executive Officer Steve Squeri told Bloomberg TV that the move will affect about 3,500 jobs. - Moderna (MRNA) plummeted after data on the companies' widely anticipated melanoma vaccine wasn't enough to prove to investors that a new era of cancer treatments has arrived. While the results clearly showed the vaccine worked, they weren't spectacular enough to generate confidence.",
                "category": "company",
                "datetime": 1792769578,
                "headline": "Decker Outdoor Tumbles on Guidance; Amex to Cut Workforce | Stock Movers"
              },
              {
                "id": 143136269,
                "url": "https://finnhub.io/api/news?id=078d4492b68de2d6e69cef66f0facd333e0d494ca796921d79b640fe4efc1e40",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna falls despite positive phase III cancer therapy data showing reduced melanoma recurrence and metastasis risks, as investors weigh elevated expectations.",
                "category": "company",
                "datetime": 1792768080,
                "headline": "MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress"
              },
              {
                "id": 143135827,
                "url": "https://finnhub.io/api/news?id=57fc357e81c2248edc267652f1b6b6ea45833c19c12ca9f07441717aba0d5d3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The stock fell 17% in one trading session.",
                "category": "company",
                "datetime": 1792764902,
                "headline": "Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?"
              },
              {
                "id": 143136270,
                "url": "https://finnhub.io/api/news?id=51ecc8f8f39febf61875543e6a7e03a60f16b2e1c6aaa72d1028d5f7d518d5c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers.",
                "category": "company",
                "datetime": 1792764360,
                "headline": "Moderna’s Cancer-Vaccine Data Leak Spurs Panic Selling. Wall Street Wanted a Cure."
              },
              {
                "id": 143135655,
                "url": "https://finnhub.io/api/news?id=dfda2da51be99b741dd272a028bc2be5834d34ec6e5f3eeb2cea605f9cf0e1db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers.",
                "category": "company",
                "datetime": 1792764360,
                "headline": "Moderna’s Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure"
              },
              {
                "id": 143135598,
                "url": "https://finnhub.io/api/news?id=122afabb1d922fd13fff731ae77d1b88e0baf208043574e70ed81a11821b0414",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna falls following a data leak for its developing cancer vaccine candidate.",
                "category": "company",
                "datetime": 1792764000,
                "headline": "Moderna, Meta, SpaceX, Bloom Energy, AT&T, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 143136965,
                "url": "https://finnhub.io/api/news?id=4b68f9102c24a0a936594155143e16a7099db616b50925b56cfac98ec3e72930",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares ended Friday’s session modestly lower, extending the sharp losses recorded in the previous trading sessions.",
                "category": "company",
                "datetime": 1792763367,
                "headline": "Moderna stock extends losses as investors digest melanoma vaccine trial data"
              },
              {
                "id": 143136266,
                "url": "https://finnhub.io/api/news?id=b51a99ecbc86eb2cf36cde243edc5499ef1f805943927a44150deb1ecac56d1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock stabilized on Friday, reversing the prior session's steep sell-off.",
                "category": "company",
                "datetime": 1792763367,
                "headline": "Moderna trims losses as investors digest melanoma vaccine trial data"
              },
              {
                "id": 143135653,
                "url": "https://finnhub.io/api/news?id=a63aefb2f3f1eea736cd58675cbf21a3e40c05a3fbc590c79ec9225e0be03940",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.",
                "category": "company",
                "datetime": 1792763367,
                "headline": "Moderna stock extends decline after leaked data on melanoma vaccine trial"
              },
              {
                "id": 143133316,
                "url": "https://finnhub.io/api/news?id=1296d63edc9ec7a266a4c9e382b0a91977461335d8f8ce0b80ad3a2863319b1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Tech stocks wobbled on Friday as the overall market declined.",
                "category": "company",
                "datetime": 1792762944,
                "headline": "Stocks extend declines, 10-year Treasury holds below 5%: AlphaCheck"
              },
              {
                "id": 143133429,
                "url": "https://finnhub.io/api/news?id=5951d905afce950044c9d6e2bfe16ba48e29264a08468d6e9fd7f0eddd417f3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the data actually delivered what investors spent months betting on.",
                "category": "company",
                "datetime": 1792761473,
                "headline": "Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip"
              },
              {
                "id": 143133474,
                "url": "https://finnhub.io/api/news?id=ed12e584f4cf1f3c6ddfea388acf97feb4398507d99cef7b2347e92c993a41ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "According to The Fly, multiple analysts commented on Moderna’s Phase 3 melanoma-vaccine data, with Bernstein describing the stock’s decline as a “sell the news event” and TD Cowen calling the leaked results “compelling” .",
                "category": "company",
                "datetime": 1792760656,
                "headline": "MRNA Stock: Citi Questions Whether Melanoma Vaccine’s Benefit Justifies Individualized Tumor Harvesting And Manufacturing"
              },
              {
                "id": 143165620,
                "url": "https://finnhub.io/api/news?id=823be31351a18e61f9d434f1e72c03cc2136ded92681a0b4b4dccd92a463a469",
                "image": "https://image.cnbcfm.com/api/v1/image/108325156-1782165442035-gettyimages-2282302541-US_GAS_PRICES.jpeg?v=1792780285&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Here are some of the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1792760144,
                "headline": "Stocks making the biggest moves midday: Chevron, CrowdStrike, American Express, SK Hynix & more"
              },
              {
                "id": 143133585,
                "url": "https://finnhub.io/api/news?id=b3bec85089c1f2451b0c9882c938a79e4c5159c44e08991e07b9b5b9d1b2d5f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The results were leaked two days before their scheduled presentation at the first Presidential Symposium of ESMO 2026.",
                "category": "company",
                "datetime": 1792760080,
                "headline": "ESMO26: MSD and Moderna drop cancer vaccine trial data early"
              },
              {
                "id": 143132979,
                "url": "https://finnhub.io/api/news?id=f7aeafe2d5b153f5909d94565469f4bc1606dd552cf8f7821b8778b910e7a703",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 premarket scan: CCI and SBAC led gainers, while TYL and DECK topped declines ahead of the open.",
                "category": "company",
                "datetime": 1792758963,
                "headline": "S&P 500 Premarket Movers: CCI and SBAC Lead Gainers, TYL and DECK Top Decliners"
              },
              {
                "id": 143165684,
                "url": "https://finnhub.io/api/news?id=ff8a7a374537504b8c0015e5ccd610e4216c5c9a23f9ca29a187529fd4628de2",
                "image": "https://image.cnbcfm.com/api/v1/image/108452245-17927717781792771776-49185199708-1080pnbcnews.jpg?v=1792771778&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Myles Minter, research analyst at William Blair, joins ‘Squawk on the Street’ to discuss Moderna as the stock took a hit following a leak of partial cancer vaccine data.",
                "category": "company",
                "datetime": 1792757717,
                "headline": "William Blair analyst on Moderna’s stock plunge following cancer vaccine data leaks"
              },
              {
                "id": 143133588,
                "url": "https://finnhub.io/api/news?id=7e645acac690c30653ce1cda094ed3bfd08fae091ef59ec20e1a8762d48eb8d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Morning Bull - US Market Morning Update Friday, Oct, 23 2026 US stocks look set for a cautiously positive open, with S&P 500 futures hovering slightly higher. The single driver this morning is labor strength, as fresh jobless claims signal a still resilient employment backdrop. Initial unemployment claims came in at 194,000 for the week ended October 17, the lowest level since July. Continuing claims held at 1.728 million. Together, those figures point to limited layoffs and ongoing...",
                "category": "company",
                "datetime": 1792757548,
                "headline": "US Stock Market Today: S&P 500 Futures Steady On Strong Jobs And PMI Focus"
              },
              {
                "id": 143128923,
                "url": "https://finnhub.io/api/news?id=842775a4a00dd1343a36615933b5601d7e4c8059640d2be7c19396a352aeedeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 and Nasdaq tumbled below 50-day lines as Meta led an AI stock rout. But the Warren Buffett market is thriving.",
                "category": "company",
                "datetime": 1792756738,
                "headline": "Dow Jones Futures Fall After Moderna Crashes, Meta Fuels AI Meltdown. Warren Buffett Market Is Thriving."
              },
              {
                "id": 143133338,
                "url": "https://finnhub.io/api/news?id=3a402816244c9b23e4ca0b8ee23de4fec223567ee98c868e0a7ab6187912a4df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The stock market is reeling from the AI selloff, a Moderna data leak, and high oil prices aren’t helping.",
                "category": "company",
                "datetime": 1792755660,
                "headline": "Stock Market Reels From 2 World-Changing Factors"
              },
              {
                "id": 143165685,
                "url": "https://finnhub.io/api/news?id=82b757a9d69a6c04d8a8c24e09045c8986a5c526f71457723d45b3b9669a7548",
                "image": "https://image.cnbcfm.com/api/v1/image/108250093-17678956902026-01-08t180322z_237136326_rc28ldawa07r_rtrmadp_0_usa-vaccines-hpv.jpeg?v=1767895707&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.",
                "category": "company",
                "datetime": 1792754591,
                "headline": "Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction"
              },
              {
                "id": 143132369,
                "url": "https://finnhub.io/api/news?id=520ade087e404d06bc724ba197cedceb5cc148fb146435d9e9e913db81f5cbf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.",
                "category": "company",
                "datetime": 1792753200,
                "headline": "Moderna Named a Top Employer by Science for Twelfth Consecutive Year"
              },
              {
                "id": 143132241,
                "url": "https://finnhub.io/api/news?id=52583a86016f59a1ab4a26fb91db39681d7e7d5e880d440ea2d6af10e0447e10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stock futures pointed lower as oil prices climbed above $114 a barrel, but some of the hard-hit tech names were enjoying a modest rebound.",
                "category": "company",
                "datetime": 1792752300,
                "headline": "Moderna, Meta, SpaceX, AT&T, CoreWeave, Sandisk, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 143130189,
                "url": "https://finnhub.io/api/news?id=583f133c259f1e9bfb6281ac85f01c5268699b8c4a4d2abeee34c44821070ce4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Friday's",
                "category": "company",
                "datetime": 1792751812,
                "headline": "Social Buzz: Wallstreetbets Stocks Mixed Premarket Friday; SpaceX to Advance, Moderna to Decline"
              },
              {
                "id": 143132879,
                "url": "https://finnhub.io/api/news?id=5b067070efaec2d52607c6f04489e0549f9a17d2c8e6db7f32a612fae6bda216",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Key Stats for Merck StockPrice change for Merck stock in last 6 months: 28%$MRK Stock Price as of Oct. 21: $14752-Week High: $157$MRK Stock Price Target: $159__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__>>> What Happened?Moderna and Merck (MRK:NYSE) shared results from a large melanoma trial on Thursday.",
                "category": "company",
                "datetime": 1792751439,
                "headline": "Moderna And Merck Cancer Vaccine Cuts Melanoma Death Risk By 42%"
              },
              {
                "id": 143128984,
                "url": "https://finnhub.io/api/news?id=5922972d586f65fcf83214c46c06e90ef1c3a8fbb7f6857fb86f2fb48028df32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stocktwits retail sentiment for SPY and DIA was ‘extremely bearish,’ while it remained ‘bearish’ for QQQ.",
                "category": "company",
                "datetime": 1792750428,
                "headline": "Nasdaq, Dow, S&P 500 Futures Drop Premarket: NVDA, AMD, META, CRWV, MRNA, WDC, BE In Focus"
              },
              {
                "id": 143165463,
                "url": "https://finnhub.io/api/news?id=dc28cb27bf68334c0760dce005d4940913be7ea4a52dc5b872c79dbbe8fdebc9",
                "image": "https://image.cnbcfm.com/api/v1/image/108451757-17927635891792763586-49183155202-1080pnbcnews.jpg?v=1792763588&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Merck CEO Rob Davis joins 'Squawk on the Street' to discuss leaked data of melanoma vaccine trials, the drop off the company's stock price and more.",
                "category": "company",
                "datetime": 1792750168,
                "headline": "Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful"
              },
              {
                "id": 143134300,
                "url": "https://finnhub.io/api/news?id=9dcb1cfe8efa32abf17e26018314b97681e3af4b21f75ce72033245902b9a7b0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/23/Moderna-vaccine.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna slides in premarket trading post ESMO data leak, despite Phase 3 vaccine trial showing a 42% cut in melanoma recurrence.",
                "category": "company",
                "datetime": 1792744547,
                "headline": "Moderna Stock Slides Again Friday: What's Going On?"
              },
              {
                "id": 143133051,
                "url": "https://finnhub.io/api/news?id=6745f97827a86b6afb7fa3368d3eac14276ad39f387bf56cd1159331d119cbfd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/23/Intel--Deckers-Outdoor--Unitedhealth--Do.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "U.S. stock futures fell, led by Deckers down 9% after mixed results and reduced FY27 guidance. BayCom, ROLR, Trulieve and others also slid premarket.",
                "category": "company",
                "datetime": 1792742515,
                "headline": "Deckers Outdoor Posts Mixed Q2 Results, Joins BayCom, Five Point Holdings And Other Big Stocks Moving Lower In Friday’s Pre-Market Session"
              },
              {
                "id": 143124377,
                "url": "https://finnhub.io/api/news?id=35a567ab400cc509afa96f335189f8350dc665d14e7053e42fbeb4de7d7c049c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792742436,
                "headline": "How Much Downside Is Left In Moderna Stock?"
              },
              {
                "id": 143165675,
                "url": "https://finnhub.io/api/news?id=65f67dca8e8c0627f05fe326b82e3e01671b18680048120912960a93c05bd5b8",
                "image": "https://image.cnbcfm.com/api/v1/image/108447865-1792693574300-gettyimages-2298258077-TSCHNEIDER_73727_Moderna_P8989578.jpeg?v=1792693614&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves in early trading.",
                "category": "company",
                "datetime": 1792741263,
                "headline": "Stocks making the biggest moves premarket: AT&T, SpaceX, Moderna, Deckers, Bloom Energy and more"
              },
              {
                "id": 143121216,
                "url": "https://finnhub.io/api/news?id=004e4f34dff2f43cd79013b56b4feb03f4fa327632bb0a2bb5544b7a79fe3ccc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA:NASDAQ) stock sank 17. 6% on Thursday to close at $202.",
                "category": "company",
                "datetime": 1792735104,
                "headline": "Moderna Sinks 18% on Leaked Melanoma Data: “Benefit Was Greater After Six Months”"
              },
              {
                "id": 143115314,
                "url": "https://finnhub.io/api/news?id=135b43f209228515c50952a30349ee08c7e868654d32617fa44767dd6167e5ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna fell up to 25% despite a cancer vaccine that cut melanoma recurrence or death risk 42%, as expectations ran high.",
                "category": "company",
                "datetime": 1792731060,
                "headline": "Moderna Slides Up to 25% as Cancer Vaccine Meets Sky-High Expectations"
              },
              {
                "id": 143115437,
                "url": "https://finnhub.io/api/news?id=a4bc98603117481f954d7ce3da9cc7042d259c1be73dd507f6d1e7008593906c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna spent much of 2025 caught between bullish hopes for mRNA expansion and bearish warnings about shrinking COVID demand and tighter pricing. For Moderna shareholders, the return over the past year was 671.9%, including dividends. If you had been weighing those sharply different analyst views in October 2025, how would you have judged the odds that such an extreme outcome could follow from the business that was on record then? The move put Moderna in the middle of this trade. Scan 36...",
                "category": "company",
                "datetime": 1792729577,
                "headline": "After Moderna's 672% Climb, The Story Has Changed"
              },
              {
                "id": 143112300,
                "url": "https://finnhub.io/api/news?id=14ce11132406f5225a528e25eed0faa1eb1f096d9f796ad378b19c0c849254fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its personalized cancer vaccine leaked ahead of a planned presentation this weekend, and the stock sold off hard even though the results themselves look positive. According to CNBC, shares fell as much as 25% after an early look at the vaccine Moderna is developing with Merck, intismeran autogene, showed up online before it was supposed to be presented at the Eur",
                "category": "company",
                "datetime": 1792721153,
                "headline": "Why Moderna (MRNA) stock is trading lower today"
              },
              {
                "id": 143110890,
                "url": "https://finnhub.io/api/news?id=a93087b565be4402a09f764630c5f9ce6c76c82457785cdd8843f4bc756767ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.",
                "category": "company",
                "datetime": 1792718929,
                "headline": "MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings"
              },
              {
                "id": 143106497,
                "url": "https://finnhub.io/api/news?id=0d7ffdcf4427521e05413591a8631472cb0162192a6e2e7685c51bc24ce4d641",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares tumbled after leaked cancer vaccine trial data showed promising results for its treatment developed with Merck.",
                "category": "company",
                "datetime": 1792714715,
                "headline": "Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says"
              },
              {
                "id": 143105051,
                "url": "https://finnhub.io/api/news?id=a63d881206482be9a6bc6fbf2bb9f71020d5154a1e81795bbd077716db89c988",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Meta’s plan to boost capex reignited investor concerns as more tech firms look to raise debt to fund AI growth.",
                "category": "company",
                "datetime": 1792712688,
                "headline": "Nasdaq 100 Clocks Worst Day In Four Months As Investors Grow Weary Of Capex, Elevated Debt — META, SPCX, BE, MRNA In Focus"
              },
              {
                "id": 143104035,
                "url": "https://finnhub.io/api/news?id=f2043248724c6702d304287d04dbb5fe81c19e5c040b5136715db0bbddd5dc4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 and Nasdaq tumbled below 50-day lines as Meta led an AI stock rout. But the Warren Buffett market is thriving.",
                "category": "company",
                "datetime": 1792706003,
                "headline": "Dow Jones Futures: Moderna Crashes, Meta Fuels AI Meltdown, But Warren Buffett Market Thriving"
              },
              {
                "id": 143104217,
                "url": "https://finnhub.io/api/news?id=6938d4e196ee4a22d307e89f193bff74a023d19079719f274bb0225ce732f493",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026.",
                "category": "company",
                "datetime": 1792703159,
                "headline": "Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports"
              },
              {
                "id": 143104565,
                "url": "https://finnhub.io/api/news?id=cbbc4fe71d7bc1211341125ce96f01ab5f2c67857a1ad98b015940eb3f471a5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares are taking a hit after the leak of highly anticipated details about the company’s vaccine for the skin cancer melanoma.",
                "category": "company",
                "datetime": 1792702254,
                "headline": "Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data"
              },
              {
                "id": 143104115,
                "url": "https://finnhub.io/api/news?id=a023b485c1dc54724797aed8b72ad4cbaaad31b74e27c9705cd2240a7637757e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investors were awaiting full data from the late-stage trial of intismeran autogene plus Merck’s Keytruda at the European Society for Medical Oncology Congress on October 24.",
                "category": "company",
                "datetime": 1792701911,
                "headline": "MRNA Stock Plunges 18% After Leaked Melanoma Vaccine Data Misses High Hopes"
              },
              {
                "id": 143102412,
                "url": "https://finnhub.io/api/news?id=3ad6fac4998feaf7a3cce36de4f079b979912e8ef0c1d8452532ab163439766d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Dow Jones index drops as oil prices jump on new planned U.S.,-Israel strikes on Iran. Meta and Tesla fall on earnings.",
                "category": "company",
                "datetime": 1792701485,
                "headline": "Stock Market Today: Nasdaq Hit As Meta, Alphabet Slide Below Key Levels (Live Coverage)"
              },
              {
                "id": 143104116,
                "url": "https://finnhub.io/api/news?id=a9229a07253e9b701f5f789c41394791eca21ceae612f9fa6454683a52e0ea74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares tumbled as reported results for its cancer vaccine with Merck circulated ahead of a planned conference presentation.",
                "category": "company",
                "datetime": 1792700820,
                "headline": "Moderna Stock Plummets 18% After Cancer-Vaccine Data Leak"
              },
              {
                "id": 143104117,
                "url": "https://finnhub.io/api/news?id=a721aef9234b2ed58940db69de802bb922c5b86e095d903f6e93cbe34a1c0b54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "[IMAGE CREDIT: Kemal Uysal from Pexels via Canva] Key TakeawaysModerna shares fell 18% today after detailed Phase 3 results for the personalized melanoma vaccine it’s developing with Merck showed up online two days before they were due to be presented. The leaked results still look positive.",
                "category": "company",
                "datetime": 1792700389,
                "headline": "Moderna Sinks 18% on Apparent Leak of Embargoed Phase 3 Melanoma Vaccine Data"
              },
              {
                "id": 143112299,
                "url": "https://finnhub.io/api/news?id=3dcdf354fbdbc647e60a498ca0ec2ef6412ec8a6d9d44839e50daaba6ef3b163",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock sinks on leaked cancer-vaccine data. Here’s why MRNA shares aren’t particularly attractive to buy on the dip.",
                "category": "company",
                "datetime": 1792700366,
                "headline": "Moderna Stock Sinks Following Vaccine Data Leak"
              },
              {
                "id": 143104215,
                "url": "https://finnhub.io/api/news?id=f8c237cff46fe09c361177eefd29e2ac6b689d3994c99cb12a5fa0f2871241e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Market Domination Host Brooke DiPalma tracks several of the day's top trending stock tickers, including Moderna (MRNA) plunging after the trial results for its melanoma vaccine were leaked, Elon Musk reportedly investing $1 billion in Skydance (SKYD), and Spotify (SPOT) shares getting a boost after releasing third quarter results.",
                "category": "company",
                "datetime": 1792699486,
                "headline": "Moderna plunges on leaked vaccine data, Musk to invest $1B in Skydance, Spotify surges"
              },
              {
                "id": 143104114,
                "url": "https://finnhub.io/api/news?id=f3965b526c03d90aa532f40b017612929f7c964832752676e7b0dd5da1222fb3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index adding 1.7% and the St",
                "category": "company",
                "datetime": 1792698970,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 143103704,
                "url": "https://finnhub.io/api/news?id=23391686c3b47b3974db762157e719e0f3235f591dd70745cc64423e7a54aed0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The stock fell up to 25% even though the data that was leaked was positive in relation to Wall Street's expectations.",
                "category": "company",
                "datetime": 1792697593,
                "headline": "Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging."
              },
              {
                "id": 143103698,
                "url": "https://finnhub.io/api/news?id=f4dc7eda199a290b72237300bcb145f84898ed83b121b89fdae3030985175fcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.",
                "category": "company",
                "datetime": 1792697220,
                "headline": "Moderna, Merck shares fall on eagerly anticipated cancer vaccine results"
              },
              {
                "id": 143103701,
                "url": "https://finnhub.io/api/news?id=d8c6dc87b4f16ba025a5da0f00169299df8b421bc161edb562cb18403fd42ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock crashed Thursday after a third-party leaked the cancer vaccine data ahead of a hotly anticipated presentation.",
                "category": "company",
                "datetime": 1792696970,
                "headline": "Merck, Moderna Unveil Cancer Vaccine Data — After A Leak Stole Their Thunder"
              },
              {
                "id": 143103702,
                "url": "https://finnhub.io/api/news?id=8cde765708a69d3d9598dbeac3a340b74cc35061bbf604e8cdcf412cbd28310c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Leaked results from Moderna's melanoma vaccine trial have the stock challenging its worst day ever, while the rest of healthcare rallies.",
                "category": "company",
                "datetime": 1792696487,
                "headline": "Moderna stock crashes as leaked melanoma data threatens its record August rally"
              },
              {
                "id": 143103966,
                "url": "https://finnhub.io/api/news?id=391c657cf8b8bd35500edd8dd058ed723150150e5d1af02abfbbe21633204915",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Roper Technologies, Allegion and Lennar led S&P 500 gainers on Oct. 22, 2026, while Moderna, Coherent and Lumentum were among the biggest decliners.",
                "category": "company",
                "datetime": 1792695971,
                "headline": "S&P 500 Top Movers: Gainers and Losers for Oct. 22, 2026"
              },
              {
                "id": 143103699,
                "url": "https://finnhub.io/api/news?id=f17944ab83b94bc7f38923ff5899df1cd9edb7bf4e7404bb906dbb1fdee70742",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "RAHWAY, N.J. & CAMBRIDGE, Mass., October 22, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in c",
                "category": "company",
                "datetime": 1792695540,
                "headline": "Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium"
              },
              {
                "id": 143103703,
                "url": "https://finnhub.io/api/news?id=739b052c328647d4a60b81449d735c7a3a09da1800918f50429e5d41dcb0f8da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares tumbled as reported results for its cancer vaccine with Merck circulated ahead of a planned conference presentation.",
                "category": "company",
                "datetime": 1792695120,
                "headline": "Moderna Stock Plummets 25% After Cancer-Vaccine Data Leak"
              },
              {
                "id": 143103705,
                "url": "https://finnhub.io/api/news?id=58eee505c45ec41ea6a19aa70b132d975f5bafe4788214879e5064bdde7c107c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Key TakeawaysModerna Inc. (NASDAQ:MRNA) sank as much as roughly 25% intraday after apparent Phase 3 results for its personalized melanoma vaccine surfaced online ahead of an embargoed medical-conference presentation.",
                "category": "company",
                "datetime": 1792694167,
                "headline": "Moderna Stock Plunges as Apparent Leak Reveals Phase 3 Melanoma Vaccine Data"
              },
              {
                "id": 143103964,
                "url": "https://finnhub.io/api/news?id=8299da548d2bdc07e3b5fc29f69d59e6d1702055520749fc9a6a5b849f99ac4c",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Netflix, Super Micro, and Moderna were among the S&P 500's most active stocks on Oct. 22, each trading at least 18 million shares.",
                "category": "company",
                "datetime": 1792692371,
                "headline": "Most Active S&P 500 Stocks on Oct. 22: Netflix, Super Micro, Moderna"
              },
              {
                "id": 143165688,
                "url": "https://finnhub.io/api/news?id=3eac0a4d0394296292188cae823e002718da1e66d26bb938b13bf93723a7c46c",
                "image": "https://image.cnbcfm.com/api/v1/image/108448807-1792706392312-1792706058-49169690455-hd.jpg?v=1792706393&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk the drop in Moderna's stock following new cancer vaccine data.",
                "category": "company",
                "datetime": 1792692098,
                "headline": "Mizuho's Jared Holz: Moderna drop reflects high bar, not bad data"
              },
              {
                "id": 143103176,
                "url": "https://finnhub.io/api/news?id=7f9e3f4ad002ca07f85c3d06787b92f6b56cb7a5fcbb8be61dc43d3ce61cb76c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investing.com -- Moderna shares plunged more than 25% on Thursday, while Merck fell over 3%, after what appeared to be an early release of closely watched clinical trial results for the companies’ experimental cancer vaccine.",
                "category": "company",
                "datetime": 1792691420,
                "headline": "Moderna shares plunge on apparent cancer vaccine data leak"
              },
              {
                "id": 143103178,
                "url": "https://finnhub.io/api/news?id=747e49ba7dc7e14629b44223970c1901f00c92fe9388751d819f8dec23a9098a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock crashed Thursday after a third-party leaked the purported cancer vaccine data ahead of a hotly anticipated presentation.",
                "category": "company",
                "datetime": 1792690417,
                "headline": "Moderna Crashes 20% On Reportedly Leaked Cancer Vaccine Data"
              },
              {
                "id": 143103700,
                "url": "https://finnhub.io/api/news?id=c1c0061510f1fe115d1e117efb11b43804433284bcd128036ad37f445582d96b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Shares of Moderna Inc. and Merck & Co. fell after reports emerged about the results of the companies’ widely anticipated personalized melanoma vaccine, suggesting a possible leak of the data that’s slated to be released this weekend.",
                "category": "company",
                "datetime": 1792689894,
                "headline": "Moderna, Merck Shares Fall After Possible Melanoma Data Leak"
              },
              {
                "id": 143134302,
                "url": "https://finnhub.io/api/news?id=7106bc23faf22d715ef28af3d012c94449cf629b309f97c6bdac5931b8878a5b",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected stage IIB-IV",
                "category": "company",
                "datetime": 1792681515,
                "headline": "Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42%"
              },
              {
                "id": 143134303,
                "url": "https://finnhub.io/api/news?id=c9839c9fe148aecbd501cf63df521bdef0d83b1bc29093b37ce1d9838230f159",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/22/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna stock plummeted 25% following an alleged ESMO 2026 abstract leak showing lower-than-expected melanoma vaccine Phase 3 efficacy.",
                "category": "company",
                "datetime": 1792680456,
                "headline": "Why Is Moderna Stock Sinking Thursday?"
              },
              {
                "id": 143165464,
                "url": "https://finnhub.io/api/news?id=b64d42bcab76351b4024e95ac877fcd8a673c1db019d7db455ddaddc517a2507",
                "image": "https://image.cnbcfm.com/api/v1/image/108448005-17926943381792694336-49166903741-1080pnbcnews.jpg?v=1792694338&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its closely watched cancer vaccine developed with Merck. CNBC's Annika Kim Constantino reports.",
                "category": "company",
                "datetime": 1792680113,
                "headline": "Moderna shares plunge on partial leak of cancer vaccine data"
              },
              {
                "id": 143133067,
                "url": "https://finnhub.io/api/news?id=b94343e7d09ca4939fdfa2e8c229fa1d9511c966e4c24fd4c2fe7c3c4b810018",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Gainers\n\nProfusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. \nKaryopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market cap",
                "category": "company",
                "datetime": 1792674338,
                "headline": "12 Health Care Stocks Moving In Thursday's Intraday Session"
              },
              {
                "id": 143135368,
                "url": "https://finnhub.io/api/news?id=a1a4797418a550701da1a4a5b438e4b48c3a2abaca80d43001e7ce2f7756005b",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "https://x.com/ShaneStoffer/status/2113282928872767621",
                "category": "company",
                "datetime": 1792673081,
                "headline": "Watching Moderna; Shares Plunge ~15% After Popular YouTuber TOGI Reveals Full-Portfolio Put Position Against The Stock"
              },
              {
                "id": 143101464,
                "url": "https://finnhub.io/api/news?id=1e3c580f94aefafafded86221bf82263e30199b37937de614f32366e989c19b2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/22/FDA-Warns-About-Salmonella-Risks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.",
                "category": "company",
                "datetime": 1792664731,
                "headline": "FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study"
              },
              {
                "id": 143098789,
                "url": "https://finnhub.io/api/news?id=e15365b58a8ec28c9fa97e540b7c8d3b25d2dd5ebcbc877ae365f22cc7456baa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) has advanced its mRNA-based bird flu vaccine into a late-stage clinical trial, the first of its kind in pandemic influenza. The study focuses on an mRNA shot targeting highly pathogenic avian influenza, aiming to test its use in a potential pandemic setting. Moderna has said it will reserve 20% of its bird flu vaccine manufacturing capacity for low and middle income countries if the product is approved. The move of Moderna's bird flu vaccine into a late stage trial...",
                "category": "company",
                "datetime": 1792664059,
                "headline": "Moderna (MRNA) Starts Late Stage Trial For mRNA Bird Flu Vaccine"
              },
              {
                "id": 143081295,
                "url": "https://finnhub.io/api/news?id=c383e83790301e97b8ff995e1081690ae8dc5e36e5b4902ecf767c89ce8e937e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) has just been added to the NASDAQ-100 Index. This move places the biotech company alongside some of the largest non-financial companies on the exchange and is drawing fresh attention to its shares. Recent trading has been strong, with Moderna’s share price delivering a 42.14% 1 month gain and a very large year to date share price return. The 1 year total shareholder return is also very large, pointing to powerful momentum following this NASDAQ-100 inclusion. See how Moderna’s...",
                "category": "company",
                "datetime": 1792647920,
                "headline": "Is Moderna (MRNA) Fully Valued Following Its NASDAQ 100 Inclusion?"
              },
              {
                "id": 143078308,
                "url": "https://finnhub.io/api/news?id=da3a80ae6007e21c552676844adffa524bb0efa58fd0d84498c197e5a6c64cac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, Chevron and Visa shares jumped to annual highs on Wednesday amid growing Wall Street optimism around the companies and other catalysts.",
                "category": "company",
                "datetime": 1792641667,
                "headline": "Why Did MRNA, CVX, V Stocks Jump To 52-Week Highs Today?"
              },
              {
                "id": 143071826,
                "url": "https://finnhub.io/api/news?id=c373207e6655f976d7bd7d32d83951b8754ddcdee276fabf8220881d3f418589",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The latest trading day saw Moderna (MRNA) settling at $245.81, representing a +1.54% change from its previous close.",
                "category": "company",
                "datetime": 1792615801,
                "headline": "Moderna (MRNA) Rises Higher Than Market: Key Facts"
              },
              {
                "id": 143070651,
                "url": "https://finnhub.io/api/news?id=1b62adee9465d824b671604a9577ff6a79b02f5365ddfc686f83e11120e3b20b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Abbott Laboratories (NYSE:ABT) reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent publicly traded company through a tax-free distribution to shareholders. Chairman and Chief Executive",
                "category": "company",
                "datetime": 1792602265,
                "headline": "What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call"
              },
              {
                "id": 143070594,
                "url": "https://finnhub.io/api/news?id=f5abb9789bc133fffb098f2944a7386165767acd4b1709ab9cb02f60e4ad6638",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Despite rising interest rates and the uncertainty of midterm elections, Asad Haider of Goldman Sachs sees promise in Big Pharma and biotech.",
                "category": "company",
                "datetime": 1792601460,
                "headline": "Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock"
              },
              {
                "id": 143069977,
                "url": "https://finnhub.io/api/news?id=7c39446ebb9278bb2d99569bee16687e10aca18b31406bd86220786f8f187137",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The market has rewarded this biotech for its breakthroughs.",
                "category": "company",
                "datetime": 1792592400,
                "headline": "Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026"
              },
              {
                "id": 143070122,
                "url": "https://finnhub.io/api/news?id=b8213e1d0b2ae8eeb637d882c37fdcb96e3d17d5c64e2a7fb1dfa7602e1dbe19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
                "category": "company",
                "datetime": 1792591119,
                "headline": "2 Large-Cap Stocks to Research Further and 1 That Underwhelm"
              },
              {
                "id": 143067523,
                "url": "https://finnhub.io/api/news?id=03483b35f6cf49583b9ddf3394ac484c78167c22c28d16679ca79306f39c9208",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.",
                "category": "company",
                "datetime": 1792585500,
                "headline": "Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?"
              },
              {
                "id": 143101756,
                "url": "https://finnhub.io/api/news?id=f1905b7485c88479f1646e1d120742bb5e312b11affe8a506f1b3f3d32092a09",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "TD Cowen  analyst Tyler Van Buren   maintains Moderna (NASDAQ:MRNA) with a Hold and raises the price target from $40 to $90.",
                "category": "company",
                "datetime": 1792580668,
                "headline": "TD Cowen Maintains Hold on Moderna, Raises Price Target to $90"
              },
              {
                "id": 143054598,
                "url": "https://finnhub.io/api/news?id=495ba275aefeee0a07ee7e5540c293492adc286ab8a63e8e030cefd64ae8034c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "This company made headlines with its coronavirus vaccine.",
                "category": "company",
                "datetime": 1792570920,
                "headline": "Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice"
              },
              {
                "id": 143055431,
                "url": "https://finnhub.io/api/news?id=aedb156e73cbdc2aea249c66ad21fee8192146530cdf52341e4df433c428ac2e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2273415673/image_2273415673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "The S&P 500 gained 2.4% and the Nasdaq Composite 4.3% between selection dates (September 10, 2026 – October 8, 2026), while the BUZZ Index gained 3.4% despite higher yields.",
                "category": "company",
                "datetime": 1792558260,
                "headline": "BUZZ Investing: AI And Semiconductor Strength Offset Rising Yields"
              },
              {
                "id": 143032268,
                "url": "https://finnhub.io/api/news?id=48a2cbbf1adbc6051988163a49e8a13292fcdfc3889377530faed9172a32a040",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.",
                "category": "company",
                "datetime": 1792528510,
                "headline": "OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business"
              },
              {
                "id": 143031687,
                "url": "https://finnhub.io/api/news?id=9767c866ea027121f6e583a1c9d55c71caf1930dcf32f3011cf51a1089f09880",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 top movers today: Equifax and Hasbro gained over 10%, while General Motors and DaVita fell more than 7% in a mixed session.",
                "category": "company",
                "datetime": 1792523164,
                "headline": "S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall"
              },
              {
                "id": 143032118,
                "url": "https://finnhub.io/api/news?id=5706a549de19317028a89a3d0711c22462e81539f7468dfc667f38a79817cba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 Health Care Sector was on track to set a fresh closing high, leading Tuesday's broad market gains.",
                "category": "company",
                "datetime": 1792521676,
                "headline": "The Healthcare Sector Nears a New High. These Stocks Are Leading the Charge."
              },
              {
                "id": 143031303,
                "url": "https://finnhub.io/api/news?id=c73fde257ce933701e64d302334df56883dce8baee224a95a5f24da1e2b346cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .",
                "category": "company",
                "datetime": 1792521344,
                "headline": "OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports"
              },
              {
                "id": 143030218,
                "url": "https://finnhub.io/api/news?id=e747848b56e46bf9d01a9ff03a13dec6283182b4d2d7bed43caec00c1f2ac2c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock is surging ahead of a closely watched cancer data readout in Madrid, and the stakes could not be higher for a company with nearly $800 million in quarterly losses and no approved cancer product yet.",
                "category": "company",
                "datetime": 1792518806,
                "headline": "Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%"
              },
              {
                "id": 143030337,
                "url": "https://finnhub.io/api/news?id=3e6d62cb4307762cc24d905acd825a8cb960483374497293a3308d0fc618ca8d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Everest Medicines recently appointed Dr. Lakshmi Srinivasan as Senior Vice President, Head of Translational Medicine, to lead global mRNA therapeutic development and align U.S. and China research teams. The hire brings direct experience from Moderna and other major biopharma groups in mRNA cancer vaccines and translational immuno-oncology, which could influence how Everest Medicines executes on its proprietary mRNA platform and broader pipeline. We will now assess how Everest Medicines'...",
                "category": "company",
                "datetime": 1792516670,
                "headline": "Should Leadership Hire Require Action From Everest Medicines (SEHK:1952) Investors?"
              },
              {
                "id": 143027729,
                "url": "https://finnhub.io/api/news?id=a141060e79ad532325fb6aae42841b3f8307b37d1ac4af485f1ac9fafc450e75",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1792491293,
                "headline": "Moderna: Sell The Cancer Vaccine Hype"
              },
              {
                "id": 143011453,
                "url": "https://finnhub.io/api/news?id=10c4037b3f6f104f99d09839a8c3778e12c0fa7c38338132c3f43a56b7735375",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midterm election outcomes could reverse recent federal spending cuts.",
                "category": "company",
                "datetime": 1792447255,
                "headline": "Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know"
              },
              {
                "id": 143013695,
                "url": "https://finnhub.io/api/news?id=1de04184caa4d14b46eb85351a1a67146ab51409cb067786b2cc413c137ce9f7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 top movers for the Oct. 19, 2026 US session: DDOG led gainers at 6.2%, while MOS led losers at -4.65%.",
                "category": "company",
                "datetime": 1792436758,
                "headline": "S&P 500 Top Movers: Oct. 19, 2026 US Session Gainers and Losers"
              },
              {
                "id": 143013693,
                "url": "https://finnhub.io/api/news?id=cd590db40b7a91aa3c4b8aa1a584864cd72c49faa7cc4e1886a0d56716410d7e",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Palantir rose 5.05% and Ford fell 2.25% among the most active S&P 500 stocks on Oct. 19, with volume in each name below its 50-day average.",
                "category": "company",
                "datetime": 1792433162,
                "headline": "Most Active S&P 500 Stocks on Oct. 19"
              },
              {
                "id": 143010815,
                "url": "https://finnhub.io/api/news?id=65f6955d7e37181274569549bd08ac674281fe8c8e15222005245f3364c8ead6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334907481/image_1334907481.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "US equity markets faced significant selling pressure this week, with sharp declines in tech and growth-oriented stocks contrasting with strong gains across defensive, energy, and value.",
                "category": "company",
                "datetime": 1792426200,
                "headline": "ValuEngine Weekly Market Commentary"
              },
              {
                "id": 143028818,
                "url": "https://finnhub.io/api/news?id=d2778ab90b572efff5219eab520a5e44a8c50826e9b43bcac8c54fbcaed07099",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "AI-driven \"biointelligence\" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.",
                "category": "company",
                "datetime": 1792420200,
                "headline": "The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning"
              },
              {
                "id": 143006918,
                "url": "https://finnhub.io/api/news?id=5f336665f9fa1a7eb4c3fcdb242bbff8b8de8f6d4386c92b570badeb9c797fba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 25.2% gain over the past six months, beating the S&P 500 by 16.3 percentage points.",
                "category": "company",
                "datetime": 1792416535,
                "headline": "3 Healthcare Stocks That Concern Us"
              },
              {
                "id": 143007833,
                "url": "https://finnhub.io/api/news?id=65f854f318ee8ec9355143f0bb74dbc72dbee90babc38adefbe1c714c3590c6e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/19/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna shares are trading higher Monday ahead of detailed Phase 3 melanoma data due Saturday and after BofA raised its price target.",
                "category": "company",
                "datetime": 1792406274,
                "headline": "What's Going On With Moderna Stock Monday?"
              },
              {
                "id": 142992182,
                "url": "https://finnhub.io/api/news?id=76496f81480358631a4fdb5349265ccf7219ba4e626da0d1745c468f7b418512",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.",
                "category": "company",
                "datetime": 1792379713,
                "headline": "Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In"
              },
              {
                "id": 142990503,
                "url": "https://finnhub.io/api/news?id=72a381499b808a00216df9a7b830934afd347818d96ba9c1ce2e8eaadba820a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Roivant Sciences has delivered a very strong multi year share price run, which now puts a spotlight on whether the current market value lines up with what its balance sheet actually supports. With that backdrop, the live question for you is how well the stock price today lines up with Roivant Sciences' book value. Over the past 5 years the stock has returned about 393%, which puts real weight on the question of how much book value is backing each dollar of market value today. Progress toward...",
                "category": "company",
                "datetime": 1792369212,
                "headline": "Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run"
              },
              {
                "id": 142988608,
                "url": "https://finnhub.io/api/news?id=981c4939bb12dccff9bebb22223c1a799ab1e82b029f1359f5435ffb1584a732",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "It has been a volatile year for the biotech.",
                "category": "company",
                "datetime": 1792349520,
                "headline": "Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?"
              },
              {
                "id": 142986896,
                "url": "https://finnhub.io/api/news?id=df82a56df15e90495c351ce929d7cbf38d5fb8c6da4a97e9263335a6b8ff7f6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "It was a head-turning headline. Here's why the market was buzzing.",
                "category": "company",
                "datetime": 1792328700,
                "headline": "Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors."
              },
              {
                "id": 142971284,
                "url": "https://finnhub.io/api/news?id=417b4fb879081d5ade679677727209b51e3c42110dee2814fafd701b1119a294",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Sandisk is changing its business model to reduce its cyclicality.",
                "category": "company",
                "datetime": 1792302600,
                "headline": "Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?"
              },
              {
                "id": 142962591,
                "url": "https://finnhub.io/api/news?id=1bb2249de9a239eeea010dbc1202e9c3d4d7dde3eff82ace0c6a353fb6a688de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.",
                "category": "company",
                "datetime": 1792255380,
                "headline": "Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline"
              },
              {
                "id": 142958499,
                "url": "https://finnhub.io/api/news?id=b1420296c8a567dcd40c8432fd47e28578939718a62fe248eb6f1b4c039ba42a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna was recently added to the Nasdaq-100 Index after positive Phase 3 data for its personalized cancer vaccine with Merck highlighted a pivot toward oncology beyond COVID-focused products. The late-stage success of intismeran positions Moderna's mRNA platform as a potential multi-product franchise across cancer and other conditions rather than a single-therapy story. Next, the focus turns to how this cancer vaccine progress could reshape Moderna's broader investment narrative around...",
                "category": "company",
                "datetime": 1792210915,
                "headline": "Phase 3 Cancer Vaccine Success Could Change The Case For Moderna Stock"
              },
              {
                "id": 142951534,
                "url": "https://finnhub.io/api/news?id=a6ec6823402e68ad6ddd5bb35f18a9ec64b21a46ee6a9622a167015e67770089",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.",
                "category": "company",
                "datetime": 1792183740,
                "headline": "Moderna Stock Slumps, but It’s Too Early to Panic"
              },
              {
                "id": 142950922,
                "url": "https://finnhub.io/api/news?id=3d84b14e70e8d6a49ca4956cbf56c9fe1e46b415cf9dac770ae6bfdec6d22e0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields restricted market appetite for risk.",
                "category": "company",
                "datetime": 1792183419,
                "headline": "Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know"
              },
              {
                "id": 142952846,
                "url": "https://finnhub.io/api/news?id=5922d94a3abed12c8a3406d8ca67edcda453c5c0dbf98dc4e8c91e66fad73146",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2191725662/image_2191725662.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Nasdaq loses 4% on the week. WTI crude settles over $101 per barrel. Inflation worries climb but FedWatch tool stays steady",
                "category": "company",
                "datetime": 1792182000,
                "headline": "Tough Trading Leaves Indices In The Red"
              },
              {
                "id": 142950824,
                "url": "https://finnhub.io/api/news?id=74963cb0e70ab8059f861c09846021096b759eb7a9602add0dbe79b1eea9591b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.",
                "category": "company",
                "datetime": 1792179360,
                "headline": "Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather"
              },
              {
                "id": 142959212,
                "url": "https://finnhub.io/api/news?id=1623819f3bfa1555899d10dbc1cb3e08c5703c2ee3ac84cc9b6bc50bda3f12b0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Today's S&P 500 top movers include FANG, EOG, EQT, APA, NI, HONA, TRGP, KMI, RTX and NOC among gainers, while TWLO, MRNA, SMCI, DDOG and PANW lead decliners.",
                "category": "company",
                "datetime": 1792177598,
                "headline": "S&P 500 Top Movers: Today's Gainers and Losers"
              },
              {
                "id": 142959210,
                "url": "https://finnhub.io/api/news?id=b3986a48a3f5afab657ba95ce3d87f80df82d15165f29bb14aad7f91ddb88834",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 most-active stocks for Oct. 16, 2026: SMCI, F, BAC, T, PLTR, NKE, ORCL, HPE, MRNA, and PFE saw heavy volume, with sharp declines and modest gains.",
                "category": "company",
                "datetime": 1792173976,
                "headline": "Most-Active S&P 500 Stocks in Oct. 16, 2026 US Session"
              },
              {
                "id": 142949190,
                "url": "https://finnhub.io/api/news?id=c959e477e65a218a0cad05f9bd494251447e606cfc31fc5528eee170530d7ad3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change that story is the question every shareholder now faces.",
                "category": "company",
                "datetime": 1792169050,
                "headline": "Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady"
              },
              {
                "id": 142959207,
                "url": "https://finnhub.io/api/news?id=71b17cbd30cf9aa4ef3c77c0f458131845b037c6290603b9f3dd4fe992b04de2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 top movers today: HONA, EOG, EXE, NI, EQT, MSI, BKR, KMI, IDXX and SLB gained, while TWLO, MRNA, SMCI, CRWD, FTNT, DDOG, PLTR, COHR, FLEX and STX declined.",
                "category": "company",
                "datetime": 1792168603,
                "headline": "S&P 500 Top Movers Today: HONA Tops Gainers, TWLO Tops Decliners"
              },
              {
                "id": 142948002,
                "url": "https://finnhub.io/api/news?id=e586d9fa75f4bb019a822871751834ee14425871a48920ab8652e36bf3d86a7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.",
                "category": "company",
                "datetime": 1792164153,
                "headline": "Moderna stock sinks as Wall Street turns cautious following blistering rally"
              },
              {
                "id": 142948003,
                "url": "https://finnhub.io/api/news?id=9dbc95242c8d52265d5c0557a75bf5612f2300b046560659575730db61480277",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock is shedding 10% after a blistering cancer vaccine run, and the question now is whether profit takers know something the bulls don't ahead of a critical trial readout later this month.",
                "category": "company",
                "datetime": 1792162163,
                "headline": "Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put"
              },
              {
                "id": 142948004,
                "url": "https://finnhub.io/api/news?id=3baf1ee24e890652fecbebc36de430f14066942b4fdd1616633ea9c823267896",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares reached their highest close in a year on October 15, 2026, ending the session at $236.50. Investors paying that premium are betting the drugmaker is ready to grow again. To meet those expectations, its sales, nearly all from COVID vaccines, have to stop shrinking, while its newer vaccines and cancer drugs have to start selling. Has the business caught up with Moderna's share pri",
                "category": "company",
                "datetime": 1792161868,
                "headline": "What Is The Case For Waiting On Moderna Stock?"
              },
              {
                "id": 142959205,
                "url": "https://finnhub.io/api/news?id=35d2528b6f45127bfd2262dd5afe7c59219686e8daef1a82ac77cbc7871d0c8e",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "S&P 500 gap downs on October 16 include MRNA, TWLO, COHR, STX, SMCI, WDC, SNDK, P, FLEX and PANW, with declines carrying into the session.",
                "category": "company",
                "datetime": 1792161400,
                "headline": "S&P 500 Gap Downs on October 16: MRNA, TWLO and COHR Lead Declines"
              },
              {
                "id": 142945790,
                "url": "https://finnhub.io/api/news?id=00513baefbcedcb0ae3d13be5f7cb7180d45cac25350ea2e4b7eaad81dda4528",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.",
                "category": "company",
                "datetime": 1792156500,
                "headline": "This week in charts: Moderna’s massive stock run"
              },
              {
                "id": 142960590,
                "url": "https://finnhub.io/api/news?id=c5926a8a854f428679082b9816725c53cdafe5c734def83695422491bdeefea2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/16/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The Nasdaq 100 fell 1.5% at midday Friday as memory chips and AI-debt names sold off, while Fed Chair Warsh declined to rule out an October hike after hot CPI and PPI. WTI held near $96, the 10-year yield hovered around 5.1%, gold bounced toward $4,200 and bitcoin traded near $81,300.",
                "category": "company",
                "datetime": 1792153986,
                "headline": "Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today"
              },
              {
                "id": 142928564,
                "url": "https://finnhub.io/api/news?id=eafe019c62ce64669af4574e6e975ab26ea081c2dd6074fd2f03985d0eaf7773",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s upcoming cancer vaccine data, Coca-Cola’s new KFC beverage partnership and Visa’s expanding services business stoked investor interest.",
                "category": "company",
                "datetime": 1792120729,
                "headline": "Why Did MRNA, KO, V Stocks Climb To 52-Week Highs Today?"
              },
              {
                "id": 142921387,
                "url": "https://finnhub.io/api/news?id=d354ceae5bd17c60de9d2be01a6d7f7ab88d2948dad79a1837d27e89a76c5d33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the latest market and sector action, highlighting what the sell-off in CoreWeave (CRWV) and chip stocks means for the rest of the market.",
                "category": "company",
                "datetime": 1792093585,
                "headline": "As chip stocks fall, investors are turning elsewhere in the market: Chart of the Day"
              },
              {
                "id": 142921517,
                "url": "https://finnhub.io/api/news?id=8c3da465e9e0bdb90c7940172faecbe1878e4269fe6803587001c2961d490742",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna to $137 from $120 while maintaining a Neutral rating.",
                "category": "company",
                "datetime": 1792093362,
                "headline": "MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data"
              },
              {
                "id": 142920417,
                "url": "https://finnhub.io/api/news?id=0fcc6a99bb57e8d09d485a37d2e2d7d64a2221923ab8736bdb870d379724be43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why.",
                "category": "company",
                "datetime": 1792083305,
                "headline": "Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher"
              },
              {
                "id": 142919826,
                "url": "https://finnhub.io/api/news?id=5f62ae2ffc34d09948943f0a9e59acd49547181c65388b6c0146533f57da300c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.",
                "category": "company",
                "datetime": 1792082102,
                "headline": "Discover which S&P500 stocks are making waves on Thursday."
              },
              {
                "id": 142920873,
                "url": "https://finnhub.io/api/news?id=4d9aa579e79067235c8ba3c8a3f3fa01278e02da1042d19401a1dd2caa942506",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417795138/image_1417795138.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna stock is a \"Hold\" due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on pipeline execution. Read the full analysis here.",
                "category": "company",
                "datetime": 1792074246,
                "headline": "Moderna: Best S&P 500 Stock YTD Could Rally Into YE, But Valuation Is Uncertain"
              },
              {
                "id": 142945322,
                "url": "https://finnhub.io/api/news?id=8ed3e6b98969460c0fc7bfbb16db19e96e60d4cb947825faae3b2fcf5d8a1667",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/15/Defensive-Stocks-Puzzle-Utilities-Health.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Concerns about tech companies overspending on AI prompted investors to rotate out of the trade and seek value elsewhere. ",
                "category": "company",
                "datetime": 1792073724,
                "headline": "Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks"
              },
              {
                "id": 142945625,
                "url": "https://finnhub.io/api/news?id=f12791c4c64f65bdc761f41f50cf294e6c7568cd4d68f2aa11b60f5b1cd155f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "International Biotechnology Trust Plc (LSE:IBT, OTC:IBITF) portfolio manager Marek Poszepczynski spoke with Proactive's Stephen Gunnion about emerging cancer treatments, upcoming clinical trial catalysts and the trust’s fifth consecutive year of benchmark outperformance. Speaking after a therapeutics conference in Boston, Poszepczynski highlighted developments involving Revolution Medicines, AstraZeneca, Summit Therapeutics and Moderna, with a focus on potential advances in pancreatic cancer, lung cancer and melanoma. He discussed the prospects for Revolution Medicines’ pancreatic cancer treatment, AstraZeneca’s AVANZAR trial and upcoming data from Summit Therapeutics that could challenge Merck’s blockbuster KEYTRUDA. Moderna’s melanoma results also featured, with further data expected to help clarify the treatment’s potential. Poszepczynski said IBT prioritises companies addressing significant unmet medical needs, focusing on treatments that could change clinical practice rather than deliver incremental improvements. He also explained how disciplined portfolio management has helped the trust outperform its benchmark for five consecutive years. This includes selling investments when valuations reach target levels and managing exposure to high-risk clinical trial events. Acquisition activity has also contributed to performance, with Poszepczynski saying more than a quarter of the portfolio was acquired by other companies over the previous year. Watch the full interview for his views on the latest oncology developments, upcoming clinical catalysts and the investment strategy behind IBT’s performance. Visit Proactive's YouTube channel for more biotechnology, healthcare and investment interviews. Don't forget to give this video a like, subscribe to the channel and enable notifications for future content. #InternationalBiotechnologyTrust #IBT #BiotechInvesting #BiotechStocks #Proactive #MarekPoszepczynski #Biotechnology #HealthcareInvesting #Oncology #CancerResearch #ClinicalTrials #Pharmaceuticals #InvestmentTrusts #PortfolioManagement #BiotechInnovation #RevolutionMedicines #SummitTherapeutics #Moderna #AstraZeneca #Merck #Keytruda #DrugDevelopment #InvestmentPerformance",
                "category": "company",
                "datetime": 1792072066,
                "headline": "IBT manager on therapeutics conference, oncology breakthroughs and five years of outperformance"
              },
              {
                "id": 142914091,
                "url": "https://finnhub.io/api/news?id=8050d0fb56e874bfe36f92adcec961a5cef1c04ef7a04d0718b18aa317f99178",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.",
                "category": "company",
                "datetime": 1792066848,
                "headline": "Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?"
              },
              {
                "id": 142915781,
                "url": "https://finnhub.io/api/news?id=5325fd16d977cce2122399699832bb035f0ed958bfbb030ac2049e525fd40c10",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.",
                "category": "company",
                "datetime": 1792053069,
                "headline": "Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday"
              },
              {
                "id": 142918183,
                "url": "https://finnhub.io/api/news?id=b4cdfa1825a67292882031ef4b584398f3987db1a70ab883b009b373f112f235",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Goldman Sachs  analyst Salveen Richter   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $120 to $137.",
                "category": "company",
                "datetime": 1792049009,
                "headline": "Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $137"
              },
              {
                "id": 142887222,
                "url": "https://finnhub.io/api/news?id=0b7c292179b56ca652306005b9567d0a0523eab678139849606472987ea2e20f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1792004701,
                "headline": "Top S&P500 movers in Wednesday's session"
              },
              {
                "id": 142885199,
                "url": "https://finnhub.io/api/news?id=8719c4b8e9632570b216f01e32f4bd5f253af404e968afa86404db29c4b76bf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.",
                "category": "company",
                "datetime": 1791990840,
                "headline": "Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug"
              },
              {
                "id": 142882995,
                "url": "https://finnhub.io/api/news?id=5bee88da8be6c1a1e20df2f644bb864a5333799ee01c16672580138bd0beea64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.",
                "category": "company",
                "datetime": 1791985560,
                "headline": "Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug"
              },
              {
                "id": 142877597,
                "url": "https://finnhub.io/api/news?id=ee485ffa353f95fe16ec1c801f3480957cdbc1614c6525f24ae2c64f26aed4b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Gabelli Funds Portfolio Manager Justin Bergner and NYSE Senior Market Strategist Michael Reinking break down how the AI boom, rising interest rates, and geopolitical tensions are fundamentally reshaping the stock market.",
                "category": "company",
                "datetime": 1791972000,
                "headline": "What the interest rate danger zone means for your money"
              },
              {
                "id": 142852474,
                "url": "https://finnhub.io/api/news?id=288e96a0f39976996dc6855674ee391f80bb8691dcb257d54e15af7043c4f3ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?",
                "category": "company",
                "datetime": 1791903660,
                "headline": "MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?"
              },
              {
                "id": 142882290,
                "url": "https://finnhub.io/api/news?id=dad524e982dd6c58bdb1fa3180264aef3534e3fa2d3d927ace66c7ffc4b03f05",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1791898511,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142848926,
                "url": "https://finnhub.io/api/news?id=9a21bc6679040d47af2b097ddec1264df35938cafcc4522683542e78d36acb1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a discussion panel entitled Competing in a New Global Playing Field.",
                "category": "company",
                "datetime": 1791896520,
                "headline": "Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026"
              },
              {
                "id": 142848728,
                "url": "https://finnhub.io/api/news?id=4ff718c0d17dfa447f9637b4c4aecc5e4e89c933ebad91449ca247f2ad041a9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.",
                "category": "company",
                "datetime": 1791895025,
                "headline": "Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142847926,
                "url": "https://finnhub.io/api/news?id=123cdc6d0ab0a2796cf336c8a3776abd50b85fd1ff13a6aa674423cb8464ac24",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1791894901,
                "headline": "Tuesday's pre-market session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 142847594,
                "url": "https://finnhub.io/api/news?id=2f0115d035c32c47a669478e2f0a61b88dc4f37e834405d995eea48d7da51293",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a. ET on Friday, November 6, 2026 to report its third quarter 2026 financial results, and provide a corporate update.",
                "category": "company",
                "datetime": 1791889200,
                "headline": "Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026"
              },
              {
                "id": 142848040,
                "url": "https://finnhub.io/api/news?id=9e6dafae442f96026a265b8b3c3d2e060891d304bc6b6f2278911b4ff4a22654",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253962329/image_2253962329.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "U.S. equity markets were mixed this week, with broader gains across value, defensive, and cyclical sectors offset by weakness in technology and the NASDAQ 100.",
                "category": "company",
                "datetime": 1791882900,
                "headline": "ValuEngine Weekly Commentary With Strategy Notes"
              },
              {
                "id": 142841955,
                "url": "https://finnhub.io/api/news?id=f26ca8df2edfe36d48bbd35dad4514614cc7a7b79061094506f25b8be0158498",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Is bigger always better? Not necessarily.",
                "category": "company",
                "datetime": 1791882240,
                "headline": "Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?"
              },
              {
                "id": 142844367,
                "url": "https://finnhub.io/api/news?id=66560ff9f3f37bf54fdf7009dcfee55437ea1d91b6ce9ebd018012482868e7b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242072348/image_2242072348.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "From June we saw money rotate out of tech into reflationary sectors, also software, explains Amrita Roy and Uttam Dey. Now, money is moving back into tech.",
                "category": "company",
                "datetime": 1791873000,
                "headline": "S&P Hits All-Time Highs, AI Trade Does All The Work"
              },
              {
                "id": 142832198,
                "url": "https://finnhub.io/api/news?id=d3ea8e257978166d5e746743c7288a47771d0314699386d25faf85b0c5e2d4a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Key TakeawaysModerna stock surged 14. 2% on October 9 after reports of an NIH-backed initiative to accelerate cancer vaccine development.",
                "category": "company",
                "datetime": 1791858206,
                "headline": "Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines"
              },
              {
                "id": 142824554,
                "url": "https://finnhub.io/api/news?id=44630c809357e2f07010f9d4cdb465c71d19dd1f54e2d65b83653012ff28c8ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the company's sales have fallen for three consecutive years, and nearly all of that revenue still comes from COVID vaccines. This divergence suggests investors are placing heavy bets on a product Moderna does not sell yet. So what is Moderna getting ready to sell, and how far along is it.",
                "category": "company",
                "datetime": 1791838902,
                "headline": "Where Could Moderna's Next Growth Come From?"
              },
              {
                "id": 142824630,
                "url": "https://finnhub.io/api/news?id=43df23e601f4825f694952c4d6c8d28928860c31593421aec5e57e82831752db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In the closing of the recent trading day, Moderna (MRNA) stood at $213.63, denoting a -5.05% move from the preceding trading day.",
                "category": "company",
                "datetime": 1791838203,
                "headline": "Here's Why Moderna (MRNA) Fell More Than Broader Market"
              },
              {
                "id": 142823403,
                "url": "https://finnhub.io/api/news?id=7d346a60f670e8f9ddc8279296e8c4fd9cae67d242e655a952cce9bcd63808f9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791831901,
                "headline": "Discover which S&P500 stocks are making waves on Monday."
              },
              {
                "id": 142822735,
                "url": "https://finnhub.io/api/news?id=0d838ad684b027caa0cf0df8d0c80c8fb4001955df05b1ec8d509ebe13fd36bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The vaccine maker's stock gained 18% last week after a report on a planned NIH cancer vaccine initiative and its addition to the Nasdaq-100",
                "category": "company",
                "datetime": 1791826428,
                "headline": "Moderna stock surges more than 600% in 2026"
              },
              {
                "id": 142822732,
                "url": "https://finnhub.io/api/news?id=dc400d678e5afb7aec6e1693488e62f662c93be576b78ff8f0f53e7d71d9c2e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Merck (MRK) is back in focus after reporting positive Phase III results from its personalized mRNA cancer vaccine program with Moderna, a development now linked to a planned public private cancer vaccine partnership. Recent headlines around Merck’s mRNA cancer vaccine work sit alongside a busy few weeks that included the SPR2015 KRAS licensing deal, new adult access to CAPVAXIVE in Ontario, and an early trial start using Cyprumed’s oral delivery technology. Against that backdrop, Merck’s...",
                "category": "company",
                "datetime": 1791824861,
                "headline": "Merck (MRK) Could Be 7% Below Fair Value On Phase III Cancer Vaccine Results"
              },
              {
                "id": 142821651,
                "url": "https://finnhub.io/api/news?id=c9d831442b9c1045fb85a7b44fe95907e600ec62df59c720cb57891bfd1f67cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.",
                "category": "company",
                "datetime": 1791816360,
                "headline": "Tempus AI Expands Strategic Collaborations to Drive Future Growth"
              },
              {
                "id": 142821797,
                "url": "https://finnhub.io/api/news?id=101e25e7c4ca9a920679bb28ba1c583059215c31ea63222d3ce3d0ee418bae7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and human control concerns dominated recent industry discussions, the quarterly letter highlights the massive, untapped potential of deploying existing AI capacity into industrial applications. The letter […]",
                "category": "company",
                "datetime": 1791815227,
                "headline": "Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp Stock Rally"
              },
              {
                "id": 142821652,
                "url": "https://finnhub.io/api/news?id=1d256551eb6855fe5613b6462f6afe2fd779b9bd9aba8f8ba545910b1137d5a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.",
                "category": "company",
                "datetime": 1791814320,
                "headline": "Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines"
              },
              {
                "id": 142819797,
                "url": "https://finnhub.io/api/news?id=da93845afd3b4bf11846e0e74f24619b7acfd2d2516cd5d52ffd7d3f8a522f5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stocks were little changed on Monday ahead of a big earnings week.",
                "category": "company",
                "datetime": 1791812522,
                "headline": "Tech slumps as oil prices rise, focus turns to earnings season kickoff: AlphaCheck"
              },
              {
                "id": 142822445,
                "url": "https://finnhub.io/api/news?id=6a9b5a81416b333cfcb565f96c7c45b8def604f362c6a7ebf08f6f14592ed8fb",
                "image": "https://image.cnbcfm.com/api/v1/image/108398008-17918081451791808141-48951856214-1080pnbcnews.jpg?v=1791808144&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the public-private push to accelerate cancer vaccine development, his thoughts on the current flu season, AI integration in hospitals, and more.",
                "category": "company",
                "datetime": 1791795999,
                "headline": "Dr. Scott Gottlieb on push to fast-track cancer vaccines, flu season and AI integration in hospitals"
              },
              {
                "id": 142816306,
                "url": "https://finnhub.io/api/news?id=330fbaf9b5174030e308e65d940a51f4bcbe56e9b042ae7e7722b12c2bf35252",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Forget the \"Magnificent Seven\" in favor of the \"Tremendous Three\"?",
                "category": "company",
                "datetime": 1791795840,
                "headline": "These 3 Stocks Are Crushing the \"Magnificent Seven\" This Year -- Are They Still Buys?"
              },
              {
                "id": 142819667,
                "url": "https://finnhub.io/api/news?id=7a635c49ac41617cd1ad673f2d4a6c50cf6070ab530de9320081ef1197b68a98",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Doctors--Tablet-And-People-With-Discussi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Palantir CTO Shyam Sankar calls AI doomsday predictions theological, while warning that extreme optimism amounts to ‘mass psychosis,'",
                "category": "company",
                "datetime": 1791795613,
                "headline": "Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’"
              },
              {
                "id": 142819668,
                "url": "https://finnhub.io/api/news?id=99434cce829fc22f2fec5d8aa6a330985e5f0d6f9f7ce48d33775dc15d6b2ee2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Stephen-King-at-New-York-Comic-Con.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.",
                "category": "company",
                "datetime": 1791781934,
                "headline": "Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'"
              },
              {
                "id": 142811129,
                "url": "https://finnhub.io/api/news?id=aa4e6af2649f3f9eeb6605ff7b67664cda878a49a5317f2d94fbdf632020f8e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The rallies highlighted growth opportunities across biotechnology, health insurance and optical technology.",
                "category": "company",
                "datetime": 1791774188,
                "headline": "Why Did MRNA, HUM, LITE Stocks Surge To 52-Week Highs Last Week?"
              },
              {
                "id": 142806504,
                "url": "https://finnhub.io/api/news?id=f878fb480560c54695b440396708c4874208ab84ae6a77ef66a66f1a2b97bd9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, Inc. was added back to the Nasdaq-100 index and earlier announced that former manufacturing leader Juan Andres would return as Chief Operating Officer to oversee scaling for its personalized cancer vaccine candidate, intismeran autogene, following positive Phase 3 melanoma results. This combination of index inclusion and operational leadership focused on oncology suggests Moderna is entering a new phase of portfolio diversification beyond its initial COVID-19 vaccine focus. We’ll...",
                "category": "company",
                "datetime": 1791727967,
                "headline": "Moderna (MRNA) Is Up 18.4% After Cancer Vaccine Milestone And Nasdaq-100 Return Has The Bull Case Changed?"
              },
              {
                "id": 142805345,
                "url": "https://finnhub.io/api/news?id=e83de194b1b87aaf442967a3482ff32a937dde1a527eb9cc5476c72769b7f1b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has surged back into the spotlight after a powerful share price run, which puts a fresh focus on whether the current US$225.00 level can be supported by the sales the business is generating. After that kind of move, the key issue for anyone looking at the stock is how its revenue base lines up with the price now being asked in the market. The stock has delivered a very large 1 year return of about 7x, which raises the stakes on whether recent performance is in line with what its...",
                "category": "company",
                "datetime": 1791720824,
                "headline": "Moderna (MRNA) Stock Looks Expensive Following Its 7x One Year Run"
              },
              {
                "id": 142805020,
                "url": "https://finnhub.io/api/news?id=e93b52c82892cafc250ab1f7952c55d1c3fc90c2321615b065e2ab862300d30d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s updated modelling now points to a slightly higher fair value estimate, with the figure moving from US$119.56 to US$122.67 per share. That shift lines up with recent analyst commentary that treats the intismeran cancer vaccine program as an important driver, even as some firms argue that higher price targets are hard to square with questions on oncology revenue assumptions. Read on to see how this evolving narrative around Moderna, its pipeline, and valuation inputs could shape what...",
                "category": "company",
                "datetime": 1791716980,
                "headline": "Moderna (MRNA) Stock Sees Modest Fair Value Lift After Cancer Vaccine Analyst Revisions"
              },
              {
                "id": 142795870,
                "url": "https://finnhub.io/api/news?id=cfea27c2bcc3854662f95ec52871962c40ba9898021bf05594b2e427776a803f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "After a few years of stagnation, this stock is soaring.",
                "category": "company",
                "datetime": 1791671700,
                "headline": "Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?"
              },
              {
                "id": 142795832,
                "url": "https://finnhub.io/api/news?id=4324a077ff4a72a38f2d5f3780564f0c42d186f4763ee7da222becfe6f97e70b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock is up 663% in 2026, beating AI names for the S&P 500 lead. Full cancer vaccine data arrives October 24.",
                "category": "company",
                "datetime": 1791671034,
                "headline": "A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year"
              },
              {
                "id": 142792628,
                "url": "https://finnhub.io/api/news?id=ff3b3be067a4c287f88208fb12b78c29d20a59d27d74e110fe1720f8e2fbea04",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1791630102,
                "headline": "The 1-Minute Market Report October 10, 2026"
              },
              {
                "id": 142792567,
                "url": "https://finnhub.io/api/news?id=11a786498782afaccf0262d5570d06ee18a18ddd114c981cf9f7594cc7351290",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Preview next week’s market-moving events—CPI, retail sales, Fed talk, and big bank earnings (JPM, GS, C, MS).",
                "category": "company",
                "datetime": 1791630000,
                "headline": "Banking Bellwethers Kick Off Earnings, Fed Chair's Speech In Focus"
              },
              {
                "id": 142769670,
                "url": "https://finnhub.io/api/news?id=9d3295f3bb1adffe88e68237811e5227ae5d48cec72684a1c0f63434b017580a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.",
                "category": "company",
                "datetime": 1791590964,
                "headline": "BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push"
              },
              {
                "id": 142771076,
                "url": "https://finnhub.io/api/news?id=f56bd64c9b264ca01fd46e7475092dc34ffa8ab476200e9a0d2c7a0ddb5ec296",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The biotech could play a significant role in a national effort to combat cancer.",
                "category": "company",
                "datetime": 1791590851,
                "headline": "Why Moderna Stock Surged Today"
              },
              {
                "id": 142767230,
                "url": "https://finnhub.io/api/news?id=32888a724310a8ebb739390192df3753f6140611aa23b6d020d6eeeaf5dfde0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares on Friday were driven by multiple catalysts, including a Nasdaq-100 entry, a New York Times report on a planned NIH-backed cancer-vaccine push and a price target hike.",
                "category": "company",
                "datetime": 1791577388,
                "headline": "MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push"
              },
              {
                "id": 142767234,
                "url": "https://finnhub.io/api/news?id=d7d5f0fd22730d92951f2014ccb62427ee49edb1d22e29743ec0b95307cbbb76",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "US equity indexes ended higher Friday after a broad-based rally and strong gains in mega-cap technol",
                "category": "company",
                "datetime": 1791577320,
                "headline": "US Equity Markets End Higher Amid Broad Rally, Strong Mega-Cap Gains"
              },
              {
                "id": 142767070,
                "url": "https://finnhub.io/api/news?id=743b0382a723cbdc32d43787735790af20fd09acef17e366f8d38a2214800229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Have Moderna’s shares risen too much, too fast?",
                "category": "company",
                "datetime": 1791577202,
                "headline": "This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street"
              },
              {
                "id": 142767233,
                "url": "https://finnhub.io/api/news?id=15826fa17b57f86c4b629b7026146c99a3f083786b9f2f3f995c106283882fad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Why Everest Medicines Stock Is Back On Investors’ Radar Everest Medicines (SEHK:1952) just added two experienced mRNA cancer vaccine scientists, Lakshmi Srinivasan, PhD, and Brandon Coder, PhD, to help advance its AI+mRNA platform and upcoming clinical programs. Those hires come at a time when Everest Medicines’ share price has been volatile, with a 90 day share price return of 7.64%, a year to date share price return down 21.9%, and a 1 year total shareholder return down 44.36%. This points...",
                "category": "company",
                "datetime": 1791576753,
                "headline": "Everest Medicines (SEHK:1952) Gains Fresh MRNA Firepower As Undervalued View Holds"
              },
              {
                "id": 142773141,
                "url": "https://finnhub.io/api/news?id=d751c85017e1302e416e6bb9ec54f81278330dd63ea7b9a76ca4adb0a9fcdc1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in playing MRNA shares at current levels.",
                "category": "company",
                "datetime": 1791573430,
                "headline": "Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine Initiative"
              },
              {
                "id": 142765953,
                "url": "https://finnhub.io/api/news?id=fa69fc8000049deee244f45ce89b56b001c6c1c2df31ee60616bdbf8d43bd682",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1791572701,
                "headline": "Discover which S&P500 stocks are making waves on Friday."
              },
              {
                "id": 142765621,
                "url": "https://finnhub.io/api/news?id=1fa9f1c674574e0933237001e1e66d77711e406a331cd57995c1136d4894f80d",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the most active stocks in the S&P500 index on Friday's session. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1791569102,
                "headline": "Explore the S&P500 index on Friday and find out which stocks are the most active in today's session."
              },
              {
                "id": 142765422,
                "url": "https://finnhub.io/api/news?id=631b204a897242e9067909ca94cf040449d481cd1c86236d331f3a110e4b093d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%. Also rallying, Moderna (NASDAQ:MRNA) shares are at $219.30, up 11%, a double-digit gain that still trails Novavax stock. Meanwhile, Merck (NYSE:MRK) shares […]",
                "category": "company",
                "datetime": 1791568782,
                "headline": "Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies"
              },
              {
                "id": 142765272,
                "url": "https://finnhub.io/api/news?id=bbe1f2ebcbdec19b2d3d7a9225e75ca95b9ff0d43fd56d4c93f423c792c747fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street",
                "category": "company",
                "datetime": 1791568225,
                "headline": "Sector Update: Healthcare Stocks Gain Friday Afternoon"
              },
              {
                "id": 142767147,
                "url": "https://finnhub.io/api/news?id=26ef6d462271e20560d857d34bb2b7d1b91d3c0bed8b86406e36dfb355f69c39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.",
                "category": "company",
                "datetime": 1791562498,
                "headline": "Moderna stock hits 4-year high on planned national cancer vaccine effort"
              },
              {
                "id": 142765274,
                "url": "https://finnhub.io/api/news?id=b511a432760eaf585dcbace8a10945d149a4dcfeb9e406c5b84325a24f8870a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.",
                "category": "company",
                "datetime": 1791562498,
                "headline": "Moderna stock jumps on planned national cancer vaccine effort"
              },
              {
                "id": 142764187,
                "url": "https://finnhub.io/api/news?id=548ea96d85965d4231150ac723e0b762e14ae359a530daca3345e608b530e44e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds finish their mechanical purchases and attention shifts back to the pipeline.",
                "category": "company",
                "datetime": 1791560934,
                "headline": "Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up"
              },
              {
                "id": 142791500,
                "url": "https://finnhub.io/api/news?id=b99251c849f7a1c45efa6bd9815de84bb2e70dac7f936818418f006549e03647",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna shares are rising Friday to a fresh 52-week high. The stock enters the Nasdaq-100 Index. Here's what you should know.",
                "category": "company",
                "datetime": 1791559092,
                "headline": "Moderna Stock Hits New 52-Week High: What's Happening?"
              },
              {
                "id": 142791501,
                "url": "https://finnhub.io/api/news?id=10b61961f7807912d26796789297a2d0c536581d343ea6718415855d204068b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.",
                "category": "company",
                "datetime": 1791558672,
                "headline": "A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally"
              },
              {
                "id": 142791211,
                "url": "https://finnhub.io/api/news?id=8515c8cafa622c1ba55b6a4727cf33da0134590c035e2163865fea16ff57ffd7",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1791552910,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142791247,
                "url": "https://finnhub.io/api/news?id=6d6a7f613588e29781ea47aa1622e652afe48f306894f204f475dfe565f02ff3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Los-Angeles--California--May-20--2024-T-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The Nasdaq 100 recovers from Thursday's OpenAI-driven selloff while T-Mobile sinks 12% on SpaceX's spectrum deal and the 10-year yield holds near 5.26%.",
                "category": "company",
                "datetime": 1791552427,
                "headline": "Stock Market Today: Nasdaq 100 Rebounds From OpenAI Scare, T-Mobile Tumbles 12%"
              },
              {
                "id": 142763629,
                "url": "https://finnhub.io/api/news?id=878e8a8319515c43d93f8a05679617ac33f23f6ab80e54cd4feeb14c139564e5",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "https://www.nytimes.com/2026/10/09/science/cancer-vaccines-nih-big-bet.html",
                "category": "company",
                "datetime": 1791543602,
                "headline": "Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times"
              },
              {
                "id": 142763365,
                "url": "https://finnhub.io/api/news?id=e8a33e2e34eb5ad9a85389b5450190ce06b03de47ad677f6b29818663259167f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Stuttgart--Germany---07-28-2023-Person-H.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.",
                "category": "company",
                "datetime": 1791543065,
                "headline": "Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday"
              },
              {
                "id": 142744648,
                "url": "https://finnhub.io/api/news?id=bc8e816542216a9dccee1141b325eaf7c674aeb28d49af3cffe9b098f92f600c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Everest Medicines (HKEX 1952.HK, \"Everest\", or the \"Company\"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. The appointments further strengthen the Company's global R&D capabilities in mRNA therapeutics, an",
                "category": "company",
                "datetime": 1791512100,
                "headline": "Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development"
              },
              {
                "id": 142739970,
                "url": "https://finnhub.io/api/news?id=17a72026cbe6ce0c10a7144d1a875f5666cdcd68f08d4a852ca83ee3857ac279",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, Inc. (NASDAQ:MRNA) traded at around $196 on October 7, up 4.81% on the day and 571.42% higher over twelve months. Nasdaq said the company will rejoin the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery. Moderna left that index in December 2024, and what has changed since is the market value […]",
                "category": "company",
                "datetime": 1791510286,
                "headline": "Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?"
              },
              {
                "id": 142731194,
                "url": "https://finnhub.io/api/news?id=faf7a0129a4c5dc62aa1fd9b26271828adef20c668387f3e65a475e6c3c97390",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "BOSTON, October 08, 2026--eClinical Solutions LLC, a global provider of digital clinical software and services, will convene global technology and biopharma leaders October 12-14 for its eighth annual client and partner conference, ENGAGE 2026. The company will host over 250 attendees at W Philadelphia, including representatives from over 75 life science organizations such as GSK, Moderna, Bayer, Takeda, Daiichi-Sankyo, Vertex, Eisai, ICON, and industry partner corporate sponsors including PwC a",
                "category": "company",
                "datetime": 1791481260,
                "headline": "eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026"
              },
              {
                "id": 142727251,
                "url": "https://finnhub.io/api/news?id=f7b2dc60e7944c418a54200a105d62bafcdc6bf6b92eaf8327925bd73a4ef4cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.",
                "category": "company",
                "datetime": 1791459720,
                "headline": "Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?"
              },
              {
                "id": 142725284,
                "url": "https://finnhub.io/api/news?id=27135e9e07b38f712fa76d28aca7aafd38bbc9d427ad47bc19efe577d51ea1a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a real runway ahead?",
                "category": "company",
                "datetime": 1791459058,
                "headline": "3 Stocks That Have More Than Doubled the S&P 500’s Return This Year"
              },
              {
                "id": 142719466,
                "url": "https://finnhub.io/api/news?id=87d19cb278158784eb0178fd4b05454844fe1c754b737dbd092cb5218c672b9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Companies In The Article are:STZ,PENG,SPCX,MRNA",
                "category": "company",
                "datetime": 1791447780,
                "headline": "Company News for Oct 8, 2026"
              },
              {
                "id": 142719471,
                "url": "https://finnhub.io/api/news?id=11e47815ee394b98e4d0ccfee74bf1eb0154b87e02373ec0c6c1996eec020d9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Morning Bull - US Market Morning Update Thursday, Oct, 8 2026 US Market stock futures are essentially flat, with E-mini S&P 500 contracts edging up only fractionally as investors weigh strong demand for imported goods against early signs of improving sentiment. The US trade deficit widened to a 17 month high of $105.6b in August, with imports hitting a record $420.8b. That points to solid consumer and business appetite, yet it can also add to price pressures through higher costs on...",
                "category": "company",
                "datetime": 1791447088,
                "headline": "US Stock Market Today: S&P 500 Futures Hold Flat As Trade Deficit Worries Return"
              },
              {
                "id": 142727055,
                "url": "https://finnhub.io/api/news?id=58bccab68fc54cae0b3b7fee41a3bfdbe01117018ca16d59a9a039d148c60a9a",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "https://www.bloomberg.com/news/articles/2026-10-08/russia-denies-report-of-second-case-of-illness-in-siberia",
                "category": "company",
                "datetime": 1791439197,
                "headline": "'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg"
              },
              {
                "id": 142708288,
                "url": "https://finnhub.io/api/news?id=a86cc9f70738734096f7a1ec3ceb9af0cdd31713eec61c58ecf1764de5d90caa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.",
                "category": "company",
                "datetime": 1791426542,
                "headline": "Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142729845,
                "url": "https://finnhub.io/api/news?id=c014997ea957db0fc1fb6fa694849438778cb31eac31201357a3ff84d06878f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Tempus, a medical testing and healthcare tech company, has partnered with industry giants like Merck and Moderna to revolutionize healthcare. Founder and chief executive Eric Lefkofsky discusses these partnerships, Tempus's financial strategy and the success and failures of AI in healthcare.",
                "category": "company",
                "datetime": 1791407580,
                "headline": "Tempus CEO on How AI Can Save Healthcare"
              },
              {
                "id": 142700318,
                "url": "https://finnhub.io/api/news?id=bbc077f2bed73509ccbbbdf77e170ed9eb13fbb99ec147f5b11a941fbe75838b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The healthcare sector stood out as one of the few bright spots in Wednesday’s trading.",
                "category": "company",
                "datetime": 1791404398,
                "headline": "Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets"
              },
              {
                "id": 142699051,
                "url": "https://finnhub.io/api/news?id=4969bb37167e933cfd7558289b21f83b2434a2d4a02d1d83b878f78ff6fb8b48",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1791399901,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 142699201,
                "url": "https://finnhub.io/api/news?id=8199d09c1f9f7471d9cef46b9b5a0f5819c04e5dd45efce183f4205620b9542b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231926077/image_2231926077.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. Read more here.",
                "category": "company",
                "datetime": 1791388080,
                "headline": "Cedar Grove Capital Q3 2026 Portfolio Update"
              },
              {
                "id": 142697301,
                "url": "https://finnhub.io/api/news?id=42cb2a379378ef1912ba87fb86ca2af6da717509d428b5bc364ccfe506c9f6ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The biotech’s VP of Drug Product Operations Michelle Rodriguez on how it works with CDMOs.",
                "category": "company",
                "datetime": 1791384194,
                "headline": "CPHI 2026: Moderna builds on its COVID-era manufacturing lessons"
              },
              {
                "id": 142727689,
                "url": "https://finnhub.io/api/news?id=111a5acaac46f167d1961c88b8fc1c3249af2292e699a5d3873804e67dbd074c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/07/Tempus-AI-Logo-On-Mobile-Phone.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.",
                "category": "company",
                "datetime": 1791380692,
                "headline": "Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure"
              },
              {
                "id": 142694830,
                "url": "https://finnhub.io/api/news?id=a910c3cf1307093aa71a865be7653c98d311d7479d788b9de6f7506bfabb510d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CHICAGO, October 07, 2026--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know",
                "category": "company",
                "datetime": 1791376200,
                "headline": "Tempus Announces Multi-Year Collaboration with Moderna and Merck"
              },
              {
                "id": 142727690,
                "url": "https://finnhub.io/api/news?id=9220abdf46470e3372153beb5281c74be58c922cc735633d91f81ebe26b79d9d",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $89 to $95.",
                "category": "company",
                "datetime": 1791370292,
                "headline": "Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $95"
              },
              {
                "id": 142690911,
                "url": "https://finnhub.io/api/news?id=254278c2e3b8fe9ad6af44a36f86ff9808090d83ad4dec8e818133c9b00eb395",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Shares of Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) declined on Wednesday after both companies rose in the previous session following reports of a suspected pneumonic plague case in Russia. Novavax shares fell 11% after gaining 20% on Tuesday, while Moderna declined 6% following a 7% increase in the prior session.",
                "category": "company",
                "datetime": 1791368781,
                "headline": "Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility"
              },
              {
                "id": 142686591,
                "url": "https://finnhub.io/api/news?id=657f9761d2dfdc2106424e37fe6311032c1767ee4783a979d1d50a82e4d87a39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys.",
                "category": "company",
                "datetime": 1791366798,
                "headline": "Dow Jones Futures Fall, Yields Rise After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys"
              },
              {
                "id": 139932206,
                "url": "https://finnhub.io/api/news?id=c42aff9b13dbfcf1a32071436d2e13e0b0dd8cc7e6a73149614855d15df8c78d",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1791362110,
                "headline": "The FDA Has Accepted And Granted Priority Review To The Biologics License Application For Daiichi Sankyo/Merck's Patritumab Deruxtecan For Pretreated Locally Advanced Or Metastatic EGFR-Mutated Non-small Cell Lung Cancer"
              },
              {
                "id": 142682425,
                "url": "https://finnhub.io/api/news?id=64c66b4613237deb437402981f92ecfd5c925207ce42fafb2074d1c2858d71e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys.",
                "category": "company",
                "datetime": 1791359399,
                "headline": "Dow Jones Future Fall After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys, But These Stocks Slammed"
              },
              {
                "id": 142683943,
                "url": "https://finnhub.io/api/news?id=24e8f76eda4c60156468bff0fa39f76a8f7dc3ca177fe672d80d92754c507ec8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) appointed former executive Juan Andres as its new Chief Operating Officer in a newly created role, giving investors additional information to weigh against a sharp recent move in the stock. Recent trading has been choppy for Moderna, with the share price down 7.8% over the past day and week, yet still posting a 28.8% 30 day share price return and a very large year to date gain, while the 1 year total shareholder return also remains very high despite a weaker 5 year record...",
                "category": "company",
                "datetime": 1791357415,
                "headline": "Moderna (MRNA) Could Be 57% Above Fair Value On New COO Appointment"
              },
              {
                "id": 142668537,
                "url": "https://finnhub.io/api/news?id=721d6d5edcfaf9ef44effdde15fa410c28c6a281fe4be4edd2c0f998f6ab351a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys.",
                "category": "company",
                "datetime": 1791322696,
                "headline": "Dow Jones Futures: S&P 500 Hits High As Astera, GE Vernova, Arista Lead Buys, But These Stocks Tumble"
              },
              {
                "id": 142669648,
                "url": "https://finnhub.io/api/news?id=180202710dc273203341b97a088d7077330217059d53f32c5a075393bde007eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The death of a Russian lab technician triggers fears of a pneumonic plague outbreak, even as health officials downplay the risk.",
                "category": "company",
                "datetime": 1791320640,
                "headline": "Pandemic Panic Is Back on Wall Street. What to Know About the Russian Plague Scare."
              },
              {
                "id": 142668643,
                "url": "https://finnhub.io/api/news?id=a530aab6542cb6f6f2fa5615475ba3036ce5d64291da8a522a1807f43791fdb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "These stocks have all soared more than 350% this year.",
                "category": "company",
                "datetime": 1791318002,
                "headline": "Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026?"
              },
              {
                "id": 142667425,
                "url": "https://finnhub.io/api/news?id=799cd2ca19736d45c52db9faa5f9160ef65f2f81c348e1bda7366c44deea05c5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the top performers within the S&P500 index one hour before the close of the markets on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1791313501,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 142667782,
                "url": "https://finnhub.io/api/news?id=5be42c579586235957ebe3854c6f16f5170e52eeb4ec0992ee781fdb6d35f2b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real, and so is the risk of giving it all back.",
                "category": "company",
                "datetime": 1791313383,
                "headline": "Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?"
              },
              {
                "id": 142666223,
                "url": "https://finnhub.io/api/news?id=77d86f15549f5f68cb794b92dd883f9ce67028af48767f3a173cdb7c589f7e8d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.",
                "category": "company",
                "datetime": 1791304502,
                "headline": "Which S&P500 stocks are moving on Tuesday?"
              },
              {
                "id": 142665693,
                "url": "https://finnhub.io/api/news?id=6269f2bea8baec5db48921fc0113fe6e796197b632a4784659dc96f9483af9ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Novavax stock slid on Tuesday after a World Health Organization (WHO) spokesperson told reporters that there was a \"low\" risk of a plague epidemic, after a 28-year-old woman who worked in a Russian anti-plague laboratory died last week.",
                "category": "company",
                "datetime": 1791302343,
                "headline": "Novavax, Moderna stocks fall after WHO calls plague risk 'low'"
              },
              {
                "id": 142665591,
                "url": "https://finnhub.io/api/news?id=4fe7eff21e7fc3ab280e5978693cc4f9850e9ea6400a8bab1ab7d9c4e8677d7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.",
                "category": "company",
                "datetime": 1791301145,
                "headline": "Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers"
              },
              {
                "id": 142664476,
                "url": "https://finnhub.io/api/news?id=293a1e63d2d9f8d35ccf43537079ef2352e40d44a0deea52ecbe4d188ab55d23",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Tuesday. Discover the gap up and gap down stocks in the S&P500 index.",
                "category": "company",
                "datetime": 1791297302,
                "headline": "Tuesday's session: gap up and gap down stock in the S&P500 index"
              },
              {
                "id": 142665590,
                "url": "https://finnhub.io/api/news?id=b8c24771ec9f2acfa0c2c2695e7d6df91fc9d0d11a2219c92c917dfea329fe3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.",
                "category": "company",
                "datetime": 1791297120,
                "headline": "Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?"
              },
              {
                "id": 142668859,
                "url": "https://finnhub.io/api/news?id=e0e128374aa47ad5a23e2076967c3d01abfff200ac3a3843cc6d371cbdfa9307",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The 8:30 Hosts Julie Hyman, Pras Subramanian, and Jake Conley outline trending stories to watch on Tuesday: AMD (AMD) CEO Lisa Su's recent comments, Paramount's (PSKY) deal with Warner Bros. (WBD) finally closing, Moderna (MRNA) and other pharmaceutical stocks climbing, and Banco Bradesco (BBD) stock jumping on Brazilian election polls.",
                "category": "company",
                "datetime": 1791297103,
                "headline": "Paramount–Warner Bros. deal finally closes: Stocks to watch on Tuesday"
              },
              {
                "id": 142663741,
                "url": "https://finnhub.io/api/news?id=631504fc4ba1b24349758aad4495c3d34a2c08ba4b66f10e9572c1680c84e8bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), since the company’s rally priced a government-purchase scenario that its product line doesn’t address. Novavax stock trades at $12.32, down 2% in morning […]",
                "category": "company",
                "datetime": 1791294963,
                "headline": "Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher"
              },
              {
                "id": 142663017,
                "url": "https://finnhub.io/api/news?id=add7b011130caf548ecd5881d8dd0693a9a2406ba8ba6069c4b9fc9aba32dd92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "One group of shareholders walks away with cash at closing. The other inherits a renamed company on a new exchange carrying roughly $80 billion in debt, and the settlement terms make the usual escape routes unavailable.",
                "category": "company",
                "datetime": 1791292245,
                "headline": "The $110 Billion Paramount-Warner Merger Closes Today. What Shareholders Need to Know"
              },
              {
                "id": 142658761,
                "url": "https://finnhub.io/api/news?id=f7f9ba42bf795a8ba5ac93ca3deca7c3b67ceeb97d78b96746a91e1219253b98",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1151934014/image_1151934014.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "US equity markets were mixed this week, with gains in tech-related areas offset by weakness across several broader market and defensive sectors. Read more here...",
                "category": "company",
                "datetime": 1791267600,
                "headline": "ValuEngine Weekly Commentary: YTD And Q3 Performance Analysis, Strategy Notes"
              },
              {
                "id": 142646063,
                "url": "https://finnhub.io/api/news?id=52f9d12bcf8e9ee5110951452e48b2ceb8d3f530e8559745f627fbfa5356b6ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.",
                "category": "company",
                "datetime": 1791257642,
                "headline": "NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'"
              },
              {
                "id": 142662717,
                "url": "https://finnhub.io/api/news?id=0af991e44b8c081ec4bcc3537f414b1df1de5d750dfde4af55ad85a15eb03f4c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/06/Combination-Products-Face-Scrutiny.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Vaccine stocks are trending on Tuesday.\n\n\n\nShares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday.\n\n\n\nModerna rose 0.17% to",
                "category": "company",
                "datetime": 1791246461,
                "headline": "Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety"
              },
              {
                "id": 142639861,
                "url": "https://finnhub.io/api/news?id=8c936846d13101d763354103e18ec0b7a6e723c479867cfd117e1ba165308aa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.",
                "category": "company",
                "datetime": 1791243744,
                "headline": "NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test"
              },
              {
                "id": 142638487,
                "url": "https://finnhub.io/api/news?id=85fbe6e259994956d206666ce9bd76965db090724695c13359d2045247dc66f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Nasdaq said on October 1 that Moderna will join the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.",
                "category": "company",
                "datetime": 1791228622,
                "headline": "MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail Echoes Valuation Concerns"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 244,
            "discarded_article_count": 211
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 15.7,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.4,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.4,
            "vcp_reason": "站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 18592950,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 20473450,
              "avg_vol_20": 19842180,
              "avg_vol_30": 18592950,
              "range_pct_10": 0.3705305320326611,
              "range_pct_20": 0.3705305320326611,
              "range_pct_30": 0.5806386230506098,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1011404860444416,
              "dist_to_20d_high": 0.2186026013832128,
              "down_shrink_days": 0,
              "breakout_level_20d": 254.48,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6381431019623455
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 11.676338361763221,
              "turnoverUsdM": 3390.7340959671697,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.3
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRNA",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 152.4132,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 23.4,
            "take_profit_price": 234.142,
            "target_multiplier": 1.6,
            "technical_strength": 1.43,
            "take_profit_percent": 17.7
          },
          "positionPoints": 1.1,
          "stopLossPoints": 0.6,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 15,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 23.2184,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 2,
      "atr_pct": 11.68
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -65.93
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2124
    },
    "kdj": {
      "d": 59.04,
      "j": 10.8,
      "k": 42.96,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 56.1
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 241996183,
      "recentSlope": -2433081.7,
      "previousSlope": 5622440
    },
    "rsi": 53.46,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 251.5623,
      "position": "SAR喺價上",
      "distancePct": 26.51,
      "previousTrend": "下降"
    },
    "ma50": 173.8566,
    "macd": {
      "macd": 12.894824890731542,
      "trend": "中性偏多",
      "signal": 17.751204660356485,
      "histogram": -4.856379769624944
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 208.8245,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.85,
      "score": 4,
      "avgVolume": 20026786,
      "currentVolume": 17051717
    },
    "derived": {
      "ma20": 210.5645,
      "ma50": 173.8566,
      "prevClose": 200.1,
      "avgVolume10": 20891232,
      "avgVolume20": 20026786,
      "changePercent": -0.62,
      "avgVolumeForScore": 20026786
    },
    "ma_cross": {
      "ma20": 210.5645,
      "ma50": 173.8566,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 210.486,
      "prevMa50": 171.146,
      "spreadPct": 21.11,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 175.1447,
      "upper": 245.9843,
      "position": "中間"
    },
    "rsi_short": 37.19,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.85
    }
  }
}

{
  "close": 198.85,
  "volume": 17051717,
  "changePercent": -0.62
}